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Abstract 
 
Protein-protein interactions between NF-κB subunits and many 
transcriptional regulatory proteins have been discussed and in some cases well 
understood, however, the structural basis of the previously described p50:p50-
Histone Deacetylase 1 (HDAC1) inflammatory repressor complex is poorly 
characterized. Understanding the mechanism of this interaction will be invaluable 
in the search for therapeutics that exploit this complex to attenuate inflammation in 
a potentially IKK-independent manner. 
We have combined in silico analysis along with in vitro peptide arrays, co-
expression and co-immunoprecipitation assays to verify potential sites of 
interaction between the p50 homodimer and HDAC1. Multiple sites of interest on 
the p50 structure determined from in silico predictions were combined with peptide 
array data to reveal clear regions of potential interaction between p50 and HDAC1. 
Detailed directed mutagenesis of one such region (the nuclear localization 
sequence) resulted in a loss of the interaction between p50 and HDAC1 in co-
immunoprecipitation experiments. Additionally, loss of this HDAC1 interaction 
appears to induce a greater pro-inflammatory response in both resting and 
stimulated conditions. These results provide the first structural evidence of a direct 
interaction and points to a specific region of p50 as the key region for p50 protein-
protein interaction. 
Establishing the rules governing this critical complex will undoubtedly assist 
in further exploration of its properties in vivo and shed light on the complex 
interactions of NF-κB transcription factors and their co-regulators. Further studies 
have the potential to identify novel tailored therapeutic targets in diseases 
characterized by both acute and chronic inflammation unencumbered by the 
drawbacks associated with the ubiquitous actions of therapeutic kinase inhibitors. 
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Chapter 1 Introduction 
 
1.1 p50: A Canonical Member of the NF-κB Family 
1.1.1 The NF-κB Family 
Nuclear Factor κ Light Chain Enhancer of B Cells or NF-κB in short, refers 
to a family of proteins, the first of which was discovered in the search for 
transcription factors that regulate the expression of the immunoglobulin κ light 
chain in B lymphocytes [1]. Today it is known that, in mammals, the NF-κB family 
consists of five distinct proteins, namely p65 (sometimes referred to as RelA), RelB, 
c-Rel, p105/p50 and p100/p52 [2]. As transcription factors, proteins which bind 
DNA and regulate the transcription of genes, they act to control a host of gene 
expression primarily involved in but not limited to cell proliferation and immune 
regulation [3]. The ability of these five proteins to regulate a wide variety of genes 
is believed to be accomplished by dimerization in various combinations. To some, 
historically NF-κB refers to heterodimers of p65 and p50 proteins, however, family 
members may combine in almost any homodimeric or heterodimeric configuration 
to drive or repress the transcription of a gene with one notable exception. In 
particular, the best studied case where a dimer does not form is that deconstructed 
by Vu et. al. [4]. They note that RelB is unable to form homodimers and is 
apparently only able to form heterodimers with p52 and p50 due to its unique 
structural evolution. RelB notwithstanding, each family member as well as its 
binding partner inform its affinity for particular DNA sequences greatly increasing 
its specificity and the numbers of potential binding sites. As a result, this family of 
transcription factors has become understood to be one of the most vital and 
responsible for the transcription of thousands of genes in multiple cell types and 
tissues. 
Seen in Figure 1.1 all five members contain an N-terminal region termed the 
Rel Homology Domain (RHD), which is an area of high sequence conservation and  
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The five members of the NF-ΚB family noting their unique structural similarities and 
differences including an evolutionarily conserved Rel Homology Domain (RHD). Other 
important elements include a Leucine Zipper-like (LZ) region unique to RelB and a 
Transcription Activation Domain (TAD) shared by class 1 family members. Class two 
members are presented in their unprocessed forms noting the presence of a Glycine Rich 
Region (GRR), used as the partial processing stop signal as well as seven Ankyin repeats 
and a Death Domain involved in their function as an inhibitor of ΚB (IKB). 
 
 
 
 
Figure 1.1 The NF-ΚB Family.  
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contains both the region that allows dimerization (Dimerization Domain [DD]) and 
DNA Binding Domain (DBD) [5].  The five proteins are further divided into two 
classes based on the presence of a Transcription Activation Domain (TAD) which 
is required to drive transcription; only present in p65, RelB and c-Rel (Class II). 
Though some of their individual functions will be discussed later, it has been shown 
that independent of dimer partner, the family has a propensity to bind enhancer 
regions of DNA with the conserved sequence 5'-GGRNNYYCC-3' (where N is any 
base and Y is any pyrimidine) which has been termed the kappa-B consensus 
sequence [5]. Knowing that each subunit has its own effects and slightly different 
preferential DNA binding sequence and that its effects can be modulated based on 
its choice of binding partner all begin to describe some of the complexity relating 
to NF-κB function. To add to this, another layer of complexity can be found in how 
NF-κB itself is activated and regulated within the cell. 
1.1.2 NF-κB Activation 
Prior to regulating gene transcription, NF-κB family members must 
themselves first be transcribed. Unlike some cases where the gene must be 
transcribed as a result of an external signal and then carry out its effect, it has been 
shown that NF-κB activation is a cytoplasmic process. This is due largely to the 
fact that NF-κB proteins are maintained in an inactive state in the cytoplasm by a 
class of inhibitory molecules known as the Inhibitors of κB (IκB). Thought to include 
IκBα, IκBβ, IκBϵ, IκBγ and BCL-3 along with p105 and p100, they inactivate NF-κB 
by binding and masking the nuclear localization signal of the subunits preventing 
nuclear translocation [2]. Additionally, IκB’s contain nuclear export signals ensuring 
they are kept mainly in the cytoplasm. It is noted that p105 and p100 are capable 
of inhibiting themselves and is a token of their unique origins. Unlike those in class 
two, these class one NF-κB subunits can be transcribed in larger forms than their 
active transcription regulation size. They must be cleaved into their p50 and p52 
subunits before they are transcriptionally active and it is in these longer regions 
which are cleaved off that one can find the distinctive ankryin repeats shared by 
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the IκB family [6].  Recently, Kravtsova-Ivantsiv et al. found that KIP1 ubiquitination-
promoting complex (KPC1), a ubiquitin ligase, was integral in the process of p105 
degradation into p50 [7].  In 2006, Moorthy et.al. found that p50 can be generated 
from p105 by the 20s proteasome in a ubiquitin independent manner and that the 
glycine rich region on p105 was the stop signal used by the proteasome in the 
processing of p105 to p50 [8]. They also noted, however, that p105 pools seemed 
to be protected from complete conversion to p50 which agrees with evidence found 
by Lin et. al. who saw that p105 is not the only source of cellular p50 [9]. They 
found that p50 can be co-transcribed along with p105 and does not necessarily 
require partial processing of p105 for its creation. Nevertheless, p105 and p100 do 
serve as cytoplasmic inhibitors of not only p50 and p52 but other subunits as well 
as in the cytoplasmic high molecular weight complexes described by Savinova, 
Hoffmann and Ghosh [6]. 
While these different IκB’s are responsible for sequestering cytoplasmic NF-
κB, IκB Kinases (IKKs) are responsible for the release of NF-κB subunits to be 
taken into the nucleus to drive transcription. Made up of three subunits, namely 
IKKα, IKKβ and IKKγ (also known as NF-κB essential modulator - NEMO), the IKK 
complex is responsible for the release of NF-κB from IκB by phosphorylation-
directed polyubiquitination and proteasomeal degradation leading to nuclear 
localization of now free NF-κB subunits [10]. Recall though that there are several 
different IκB proteins and that NF-κB subunits can form many different dimer 
combinations, so one major area of poor understanding in the current literature is 
how specific pairs are formed and whether their co-localization partner in the 
cytoplasm remains unchanged or how and if they are able to switch their partner 
once transported to the nucleus. While it is known that different subunits have 
different affinities for different IκB’s, the global picture is far from complete. 
Nevertheless, there is some understanding on the matter described in the three 
overall pathways of activation. 
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Three major pathways of NF-κB activation including canonical, non-canonical and 
alternate pathway. In the canonical pathway, inflammatory ligands including TNFα and 
LPS activate the IKK complex consisting of IKKα, IKKβ and NEMO which phosphorylates 
IκB targeting it for ubiquitination and degradation and releasing active NF-κB dimers which 
can then go on to drive gene transcription in the nucleus. In the non-canonical pathway 
stimuli such as CD40 ligand activate NIK which phosphorylates an IKKα homodimer which 
may go on to phosphorylate p100 to facilitate its conversion to p52 by partial proteasomeal 
processing. RelB:p52 is then free to enter the nucleus and drive its own subset of genes. 
The alternate pathway is the most poorly described however it is usually initiated by 
stressors such as UV damage which activates kinases such as CK2 that can directly 
phosphorylate IκBs and similarly lead to active transcription factor release. 
  
 
Figure 1.2 The NF-κB Activation Pathway.  
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In the canonical pathway p65:p50 or c-Rel:p50 heterodimers are depicted as 
being sequestered by IκBα or IκBβ respectively and through signal transduction 
mediated by inflammatory cytokines such as TNFα, the IKK complex is able to 
phosphorylate IκBα on Serine 32 and 36. This signals IκBα for polyubiquitination 
and subsequent proteasomeal degradation leading to the release and nuclear 
transport of p65:p50 [3]. In the non-canonical pathway, stress caused by viral 
means or binding of CD40 ligand to its receptor among others causes the activation 
of NF-κB Inducing Kinase (NIK) which activates IKKα which can phosphorylate 
p100, in a cytoplasmic RelB:p100 heterodimer, signaling its processing into p52, 
also mediated by a ubiquitination dependent mechanism [11]. Finally, another 
pathway described by Kato et al., describes an IKK-independent activation in which 
Casein kinase 2 (CK2), in response to Ultra Violet DNA damage, can 
phosphorylate IκBα and, similar to the canonical pathway, lead to p65:p50 
heterodimer release [12]. These pathways, summarized in Figure 1.2, make no 
mention of, and provide no explanations as to the mechanism of other types of 
dimer formations, especially homodimers and therefore do not tell the whole story 
but provide a basic framework from which to understand the complexity of NF-κB 
activation.  
1.1.3 Deactivation of NF-κB Signaling  
While work has uncovered nuances in the various pathways of NF-κB 
activation, less is known about how activation is resolved into a resting state. 
Analysis of genes transcribed by NF-κB subunits reveals that IκBs themselves are 
transcribed [13]. Since the main defined role of these proteins is to sequester 
subunits and retain them in an inactive form in the cytoplasm, this has historically 
been thought of a major potential mechanism of post activation repression of 
signaling. This view has proven controversial however as there has been little 
evidence of the IκBs’ ability to enter the nucleus and export active subunits [14]. 
While others have shown evidence of active dimer shuttling between the nucleus 
and cytoplasm of stimulated cells, the involvement of IκBs and terminators of 
signaling by active nuclear export remains unclear [15]. Nevertheless as a part of 
14 
 
their normal function, newly synthesized IκBs can once again sequester subunits 
leading to loss of signal transduction. 
In addition to eventual loss of signal though IκB re-synthesis, the ubiquitin 
system has been implicated as another major mechanism by which NF-κB signals 
can be terminated [16]. RelA has been shown previously to be a target of ubiquitin 
mediated proteasomeal degradation. Additionally, BCL3 (a previously mentioned 
IκB) has been shown to bind nuclear p50 and block its ubiquitin mediated 
degradation [17]. To do this, unlike other IκBs, BCL3 is a predominantly nuclear 
protein [18]. For p50 to require this protection along with evidence of p65 
degradation suggests ubiquitin mediated ablation of NF-κB signaling and 
degradation of active subunits as a typical deactivation pathway. The extent to 
which ubiquitin mediated nuclear subunit degradation and IκB mediated 
cytoplasmic sequestration work in concert is not well established. These could 
represent two distinct deactivation pathways that are utilized in a stimuli or even 
subunit specific manner so that the correct subset of genes are modulated in an 
appropriately.  
1.1.4 NF-κB Interactions and Modifications 
1.1.4.1 RelA/p65 
In addition to the family’s various pathways of activation, NF-κB activity is 
also under the control of numerous post-translational modifications and protein 
interactions. Among the subunits, p65 is without question the most well studied to 
date and therefore unsurprisingly it also has the most known post transitional 
modifications, many of which have been understood reasonably well. It is well 
known that p65 is a critical subunit with knockout mice displaying embryonic 
lethality due to hepatocyte apoptosis [19]. Additionally, it has be shown to play 
critical roles in immunity by transcribing Fas (an apoptosis related factor) and 
TRAF1 (Tumor Necrosis Factor receptor-associated factor 1) [20]. Often p65 is 
studied in the form of p65:p50 heterodimers but p65 has been attributed many 
functions independent of p50. Of note is its role in the transcription of c-fos (another 
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transcription factor associated with cell proliferation and differentiation) and TNFα 
mediated transcription of I-CAM1 (intracellular adhesion molecule 1) [16,17]. 
Besides these direct transcription targets, work has shown that p65 also forms 
many direct protein-protein interactions. Fazal et. al. found that p65’s interaction 
with cytoskeletal actin formed a basis for a pathway leading to its nuclear 
translocation with the assistance of thrombin [21]. Evidence by Akiyama et. al. 
showed that TNFα mediated activation of human telomerase reverse transcriptase 
(hTERT) involved direct interaction with p65 and Deng et. al. showed that β-catenin 
can interact with and inhibit p65 transcriptional activation [20,22]. Chen et. al. note 
that acetylation of p65 on lysine residues 218, 221 and 310 have marked impacts 
on its DNA binding affinity and transcriptional activity but also its association with 
IκBα [23]. Furthermore, they discovered that acetylation was caused by its 
association with p300, which was enhanced by its phosphorylation at serine 276 
and 536 and that these modifications enhanced p65 activity. Kiernan et. al. also 
found an important role for acetylation in the inactivation of p65 [24]. They propose 
that acetylation at lysine 122 and 123 performed by p300 and PCAF plays a part 
in its removal from DNA and thus subsequent nuclear exportation by association 
with IκBα. Also, Moles et. al. were able to reduce NF-κB driven fibrosis by inhibiting 
serine 536 phosphorylation, believed to be another p65 activation modification [25]. 
As seen in Figure 1.3 these descriptions are not exhaustive, however, they 
highlight the great deal of work that has been done on p65. Unfortunately, the same 
cannot be said for the other subunits, in particular, less is known about c-Rel.  
1.1.4.2 c-Rel 
Discovered as a proto-oncogene, c-Rel has most extensively been studied in the 
field of immunology since it was found that c-Rel was critical in the ability of T-cells 
to produce interleukin 2 (IL-2) [26]. Much of the work around c-Rel has involved the 
use of knockouts to highlight its role in various pathways, diseases and in one 
interesting case, head and neck cancer [27]. To date a role for c-Rel has been 
elucidated in rheumatoid arthritis, heart disease and in mice loss of c-Rel was 
shown to be protective against inflammatory bowel disease (IBD) [25–27]. 
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Current known post-translational modifications within the five subunits of the NF-κB family. 
Designations refer to positions in the human protein. Only residues which been 
experimentally verified have been included. 
 
 
 
 
 
Figure 1.3 Post-translational Modifications of the NF-κB Family. 
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Bunting et. al. have also shown that c-Rel can regulate transcription of itself in 
addition its many other targets, a trait shared by most proteins in the NF-κB family 
[28]. As it relates to post-translational modifications, knowledge about c-Rel is 
limited to work by Martin and Fresno citing the most convincing case related to 
phosphorylation at serine 503 being required for TNFα activation [28]. While Huang 
et. al. have solved the crystal structure of c-Rel and Clark et. al. have shown c-Rel 
is inhibited by IκBϵ in addition to IκBβ, very little else had been published in relation 
to the structural complexities of this subunit [29,30]. Like p65, however, c-Rel has 
been implicated in many protein-protein interactions (including CREB binding 
protein and MAPK8) which are too numerous to reasonably list here but serve to 
enforce its known importance in immune regulation [31,32]. 
1.1.4.3 RelB:p52 
Often described together with p52 due to their close association and its 
inability to homodimerize, RelB along with p52 are possibly by far the least well 
understood subunits. Evidence for RelB modification is limited to a study by 
Dephoure et. al in 2008 which provided evidence for phosphorylation at serine 37 
and 573 [33]. Many more sites of modification are noted in p100/p52 but these are 
almost all related to signals involving p100 degradation into p52 [34]. Mutagenesis 
in the same studies found that residues 247-249 were critical in p65:p52 hetero-
dimerization. Finally, RelB has been described by Vogel et. al. and Jacque et. al.  
as crucial in hydrocarbon receptor mediated transcription and an inhibitor of tumor 
growth, respectively [35,36]. While by no means capturing all of the great deal of 
work since their discovery this brief overview has hopefully highlighted some of the 
many intricacies of the NF-κB family. One subunit has yet to be discussed however, 
and is emerging as perhaps one of the most critical in the control of and balance 
of the inflammatory process. 
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1.1.5 NFKB1 - The p105/p50 Subunit 
Described previously as a class one member of the NF-κB family as well as 
an IκB in its own right, p105/p50 arguably plays a critical role in both gene activation 
and repression. As a canonical heterodimer with p65 it is able to upregulate genes 
critical to the inflammatory response such as many of the interleukins, interferon β, 
TNFα as well as CXCR7, CD40, Complement components, MHC class I and 
tapasin [37]. Conversely Cao et. al. found that unlike other subunits, p50 in a homo-
dimer configuration, along with CREB Binding protein, can upregulate the 
expression of anti-inflammatory cytokine IL-10 [38]. This anti-inflammatory role has 
made p50 an exciting new prospect for therapy since such targeted control of 
inflammation is sure to produce less side effects than the broad inhibition of 
upstream pathway kinases as attempted previously [39]. To gain a better 
understanding of its function nfkb1, the gene that codes p105/p50 found on the q 
arm of chromosome 4, was knocked out in mice. From this several different studies 
describe that though the knockout is not lethal as in p65, mice suffer from neural 
degeneration, sleep irregularities, immune response defects, apparent resistance 
to certain forms of arthritis as well as altered response to various models of injury 
[40–44]. These observations in knock outs however neither describe the complete 
role of p50 nor separates it from p105, which is known to have distinct functions. 
For example, p105 has be shown to bind G protein-coupled receptor kinase 5 and 
Prostaglandin E receptor type 4-associated protein and alters the biology of 
macrophages [45,46]. Also, it has been shown to bind the Tax protein when cells 
are infected by human T cell leukemia virus type 1 and these interactions are all in 
addition to its regulatory role as an IκB protein [47]. Perhaps most importantly, 
Beinke et. al. have shown that p105 is a direct negative regulator of TPL-2 
(MAP3K8), an important kinase in a variety of cellular pathways [48].  While 
p105/p50 may have a diverse role in cells much can be learnt from the studies that 
have been done that relate to its structure and interactions. 
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The original crystal structure of a p50:p50 homodimer bound to DNA. (PDB ID: 1NFK) 
Rendered in UCSF Chimera with rounded ribbons. Blue indicates base pairs of DNA with 
red phosphate sugar backbones. 
 
 
 
 
Figure 1.4 The p50:p50 Homodimer. 
N Terminus 
N Terminus 
C Terminus C Terminus 
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Shown in Figure 1.4 and determined by Ghosh et. al. (mouse) and Müller 
et. al. (human), the crystal structure of a p50 homo-dimer bound to DNA gave the 
first insights into the process of homo-dimerization and how p50 interacts with DNA 
[49,50]. Classically described as resembling “a butterfly with protein domains as 
wings connected to a cylindrical body of DNA”, the structure includes defined amino 
acids 39 to 350 (mouse). Although a few loops of the structure were poorly defined 
in the electron density maps, each p50 molecule appeared to have two domains 
connected by a single linking chain of amino acids. Also noted by the authors was 
that the DNA binding regions of the protein is almost exclusively made up of loops 
and not the ɑ-helices that are customarily associated with transcription factors. The 
proteins are arranged in a side by side confirmation and mirrored along the z-axis. 
Additionally, binding does not seem to greatly affect the coiling of DNA and does 
not apply significant strain to the double helix [49]. 
1.1.6 Interactions and Modifications of p50 
1.1.6.1 Posttranslational Modifications 
In addition to the crystal structure, information about p50’s post-translational 
modification is more abundant than in some of the other subunits but, like p52, 
much of it is centered on its processing from its precursor. These known 
modifications as well as an overview of all the nfkb1 gene products can be found 
in Figure 1.5. Phosphorylation events at serine 903, 907, 927 and 932 have all 
been well documented and all relate to priming p105 for ubiquitination and partial 
degradation [51–53]. Demarchi et. al. in 2003 describe a working model where 
p105 phosphorylation by Glycogen synthase kinase-3 (GSK-3β) in the first 
instance can stabilize p105 but subsequent phosphorylation by IKKs then triggers 
its ubiquitination and degradation [54]. Protein Kinase B (Akt) which is upstream of 
IKK and activates it via the TNFα pathway, has also been shown to deactivate 
GSK-3 and so it is important to remember that cross-talk between upstream 
kinases is commonplace and that activation of p50 does not happen in isolation. 
Besides phosphorylation of sites on p105 that lead to its degradation, other PTMs  
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A schematic of the gene products of the nfkb1 gene including known sites of post-
translational modification and boundaries of the p50 and IκBγ proteins. RHD - Rel 
Homology Domain. NLS - Nuclear Localization Sequence. GRR - Glycine Rich Region. 
DD - Death Domain. (Reproduced from Cartwright et. al. 2016 [37]) . Amino acid positions 
refer to locations in the human gene. 
 
 
 
 
 
 
Figure 1.5 Structure of the p105/p50 gene.  
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have been found directly on p50. Marshall and Stamler in 2001 found that cysteine 
61 on p50 could be nitrosylated, which inhibited transcription of p50 targets without 
interfering with other interactions with IκB [55]. Furia et. al. described acetylation at 
lysine 431, 440 and 441 by p300 and cAMP-responsive element-binding protein-
binging protein (CBP) [56]. They suggest that acetylation here may aid in p50 
release from IκB. Hou et. al. found that serine 337 phosphorylation was able to 
significantly increase its ability to bind DNA and that mutations at this serine as well 
as 65 and 342 (340 in mice) was able to disrupt homo-dimerization [57]. Though 
this effect could be rescued by threonine substitution at 65 and 337, mutation at 
serine 342 to threonine was unable to rescue this loss of homo-dimerization. 
Wilson et. al. confirmed and exploited this mutation (though to alanine) in a study 
that implicated p50 homo-dimers as a key repressor of chronic inflammation 
leading to hepatocellular carcinoma (HCC) [58]. In addition to the reduction in DNA 
and homodimer affinity caused by phosphorylation at serine 337, p50 has also 
been shown to be phosphorylated at nearby serine 329 [59]. Crawley et. al. found 
that S329 phosphorylation leads to a distinct shift in κB site recognition where sites 
containing a -1 cytosine have a lower binding affinity for p50 than their -1 adenosine 
counterparts [60]. They go on to suggest that S329 phosphorylation primes cells 
for DNA damage induced cell death due to this altering of binding affinity and 
maintaining genome stability. 
1.1.6.2 Mutations 
In addition to its structure and post-translational modifications, multiple 
mutations in p50 have been found in patients with numerous forms of cancer. A 
search through the COSMIC (Catalogue of Somatic Mutations in Cancer) database 
reveals 124 mutations [61]. While it is unknown if these are functional or play a key 
role in the progression of the associated cancer, some of them will no doubt play a 
part in future specific cancer work. Studies also have found that mutations in the 
promoter of p50 also increased the risk of HCC [62]. All of this evidence points to 
a critical protein that is complexly regulated and serves a diverse role as both a 
promotor and suppressor of inflammation. Nevertheless, it is important to 
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remember that, as seen with other members of the family, p50 does not impart its 
effects in isolation.  
1.1.6.3 Protein-protein Interactions 
Since proteins that directly interact with p105 have been mentioned 
previously, here, suspected interactions of proteins with p50 will be elaborated 
upon. Most often, protein-protein interactions are difficult to tease apart when 
considering transcription factors that dimerize in the manner of NF-κB since it is 
difficult to be sure of the nature of the interaction. For example, Lee et. al., found 
that SMRT (Silencing Mediator of Retinoic acid and Thyroid hormone receptors) 
interacts with p50, however it also appears to interact with p65 [63]. Though they 
go on to show it is a case of interaction with both subunits, without careful analysis 
it can be easy to attribute a binding partner to the wrong subunit. Nevertheless, 
there are many p50 protein-protein interaction that have been uncovered. 
Recall, p50 homo-dimers were able to upregulate transcription of IL-10 in 
macrophages by binding CREB [38]. He et. al., has gone on to show that this 
interaction is mediated by protein kinase g (PKG) [64]. Rudders et. al. was able to 
show that through binding of ESE-1 ( a member of the E26 transformation-specific 
transcription factor family) EST, p50 was able to regulate nitric oxide synthase, 
important in intracellular signaling [65]. Also Drew et. al. found that Interferon 
regulatory factor-2 could interact with p50 and inhibit its transcription of MHC class 
I and the β2-microglobulin genes [66]. In a paper that determined STAT3’s 
interaction with p65, it was also found that p50, independent of p65, interacts with 
STAT5b to modulate haptoglobin expression [67]. Others have shown that p50 
interacts with STAT3 to inhibit nitric oxide synthase and with STAT6 to 
synergistically induce IL-4 mediated transcription [68]. In addition to this interaction 
with the STAT family of transcription factors, p50 has been shown to interact with 
and control other transcription factors and as such indirectly control those subsets 
of genes as well. Wang et. al. showed that p50 was the subunit responsible for the 
induction of C/EBPɑ transcription which allows it to stimulate neutrophil production 
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in response to inflammation [69]. C/EBP has also been shown to remove HDAC1 
(a chromatin modulating enzyme that will be discusses later) from p50 homodimers 
to induce pro-inflammatory gene expression [70].  
This list continues and is quite extensive and points ever more to this anti-
inflammatory and repressive role of p50. Indeed, Oakely et. al. have shown that 
p50 is important in limiting the inflammatory response especially in the context of 
chronic injury [71].  These anti-inflammatory properties are perhaps highlighted 
best by its known interaction with Bcl-3. Wessells et. al.  showed that LPS induced 
TNFα expression could be inhibited by Bcl-3 through its association with p50 in 
macrophages and Collins et. al. in 2014 have shown that Bcl-3 gene repression in 
general requires this association with p50 homo-dimers in particular [17,72]. Since 
this discovery, Collins et. al. have gone on to find that the Bcl-3:p50 interaction 
occurs along the Ankyrin repeat 1, 6 and 7 of Bcl-3 and have made a mimetic 
peptide that can bind p50 in a similar manner [73]. They have also shown this 
peptide to have anti-inflammatory properties and explain that it is due to the 
protection of p50 from degradation via ubiquitination, a property believed to be held 
by Bcl-3. These ‘protected’ p50 homo-dimers are then free to compete with the 
transcriptionally active p50:p65 heterodimers for gene promoters and can severely 
dampen the activation of such genes.  
With these established interactions, it is not hard to imagine p50 as an 
important regulatory molecule in the NF-κB family serving to attenuate the function 
of p50:p65 heterodimers through multiple protein-protein interactions. In addition 
to this passive or competitive based approach to gene inhibition, others believe 
that p50 can also actively down-regulate gene transcription by its association with 
another protein, Histone Deacetylase 1 (HDAC1). 
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1.2 HDAC1 and p50: Repressors of Inflammation 
1.2.1 Nuclear Genetic Organization 
Transcription factors, like p50, bind genes in promotor regions which contain 
the specific site within the DNA sequence recognized by each protein. More 
diversity of regulation than simple gene promotor affinity exists however, and our 
understanding of the epigenetic control of genes is revealing its complexity as the 
field continues to grow. Generally, in all cells genes are organized into areas of 
active transcription (euchromatin) and regions of condensed ‘inactive’ DNA refered 
to as heterochromatin [74]. DNA strands are wrapped onto nucleosomes which are 
looped by the molecules CTCF and cohesin into either active or inactive regions 
referred to as topological associated domains [75]. These are regions where DNA 
sequences are associated in three-dimensional space but not necessarily 
sequence. It is believed that whether a region is available for transcription is tightly 
regulated by post-translational modification of both the DNA sequence itself and 
also the previously mentioned nucleosomes around which it is wrapped [74]. 
A major method by which transcription can be repressed though DNA 
modification is through DNA methylation. DNA methylation is thought to block some 
transcription factors from binding their intended sequences due to base 
modifications but also allows the recruitment of methyl-CpG-binding domain 
proteins (MBDs) which can in turn recruit more transcriptional repression 
machinery to the locus of genes intended to be switched off [76]. The target of such 
machinery is often the C-terminal tails of proteins which make up nucleosomes, 
broadly termed histones. 
Nucleosomes are octamers which consist of dimers of the tetramer histones 
H2A:H2B:H3:H4. Together, these eight proteins make up the smallest unit of DNA 
organization in the nucleus of cells and each of which are subject to a number of 
post-translational modification which have a profound effect on the transcription of 
nearby genes [74]. 
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1.2.2 Epigenetic Modification of Histones 
Histone methylation can serve to both repress and enhance gene transcription in 
a gene specific as well as histone specific manner. For example, histone 3 (H3) K9 
di or tri-methylation is a well-known silencing mark and is found on inactive copies 
of the X chromosome in females. Conversely, H3 K4 methylation is a well 
described mark of transcriptional activation. Methylation of histone tails is not the 
only post-translational modification that affects gene transcription [77]. Histones 
can also be phosphorylated at numerous sites on all four major histone variants 
which can have differing effects. A canonical marker of DNA damage is the 
phosphorylation of histone variant H2AX. With regard to gene transcription, 
phosphorylation at H3 S10, T11 and S28 along with H2B S32 have all been shown 
to have an impact on the control of highly proliferative genes [78]. These 
phosphorylation events are, in the literature, correlated with another important post-
translational modification; acetylation. Histone acetylation occurs at many residues 
along histone tails and some of the most well studied sites include K4, K9 and K27, 
all of which can also be tri-methylated [79]. Acetylation, phosphorylation and 
methylation together form a complex code on the tails of each histone molecule 
that together determine the overall accessibility of nearby genes and the numerous 
enhancers and co-factors that may bind DNA. Acetylation, however also plays a 
physical role in the organization of DNA. Acetylated histones carry positive charges 
which tightly bind negatively charged DNA. Deacetylation neutralizes this positive 
charge and decreases the affinity of histones for DNA and allows for a looser 
conformation which exposes more of the DNA to any potential binding proteins 
[79]. 
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Table 1.1.1 Relevant Epigenetic Modifications of Histone H3 
A table of well characterized posttranslational modifications of histone H3 which impart 
various outcomes on the three dimension arrangement of chromatin. 
 
 
 
Modified 
Residue 
Modification Function 
K4 Acetylation Activation of Transcription [80] 
K9 Acetylation Activation of Transcription [81] 
K14 Acetylation Activation of Transcription, Histone Deposition & 
DNA Repair [82] 
K18 Acetylation Activation of Transcription, DNA Replication [83] 
K23 Acetylation Histone Deposition, DNA Repair & 
Transcriptional Activation [83] 
K27 Acetylation Activation of Transcription [83] 
K4 Methylation Activation of Transcription [80] 
R8 Methylation Repression of Transcription [84] 
K9 Methylation Repression of Transcription & Gene Silencing 
[81]  
R17 Methylation Activation of Transcription [85] 
K27 Methylation Repression of Transcription [86] 
K36 Methylation Activation of Transcription [87] 
K79 Methylation Activation of Transcription [88] 
T3 Phosphorylation Mitosis [89] 
S10 Phosphorylation Mitosis & Activation of Transcription [89] 
T11 Phosphorylation Mitosis [89] 
S28 Phosphorylation Mitosis [89] 
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1.2.3 HDAC1: A Class 1 Histone Deacetylase 
Histone Deacetylase 1, one of 18 in its protein family, is responsible for the 
maintenance of the three-dimensional structure of chromatin by the removal of 
acetyl groups from histones that bind DNA. Once de-acetylated, histones are able 
to more tightly bind DNA, leading to gene repression in that region by denying 
access to transcription factors [90]. Due to this potent role as major ubiquitous 
modifier of 3-dimensional chromatin structure and gene expression, it is not 
surprising that loss of HDAC1 is embryonic lethal [90]. Oh et. al. found that a 
mutation of histidine to alanine at amino acid 141 completely destroys its 
deacetylase activity and thus it is known that this forms the active catalytic site of 
the protein [91]. It contains a few important sites of PTM in serine 421 and 423 
which are phosphorylated and enhance deacetylase activity and is acetylated on 
lysine 74 and 220 (Figure 1.6) [92,93]. Additionally, it has been found that HDAC1 
can deacetylate p65 on lysine 310, which promotes apoptosis  [94].  
Unlike some other members of its family, HDAC1 is an exclusively nuclear 
protein and forms the catalytic core of several nuclear remodeling complexes. 
Found along with HDAC2, HDAC1 is a known component of the Sin3A, CoREST 
and NuRD complexes [95]. Within these complexes, HDAC1 and HDAC2 act as 
the catalytic core while other components of the complex supporting this function. 
For example, it is known that Sin3A is recruited and tethered to DNA by MAD:MAX 
heterodimers [96]. The NuRD complex works in a similar way and shares a few of 
its components with the Sin3A complex [97]. Work on co-REST has found that 
HDAC1 is also a component of this complex which plays a role in the 
downregulation of neural genes in non-neural cells and has been shown to be 
important in Huntington disease and neuroblastomas [98]. Together, the presence 
of HDAC1 as the catalytic core responsible for the modulation of genes in 
numerous systems implicates it as a definitive protein required for epigenetic gene 
repression through deacetylation. 
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A. Known post-translational modifications in HDAC1. B Crystal structure of the catalytic 
core of HDAC1 (PDB ID 4BKX). Rendered in UCSF Chimera with rounded ribbons. Purple 
indicates potassium ions included in the resolved structure. Residues which participate in 
the catalytic core of the enzyme and are critical for enzyme function have been displayed 
in stick representation. The N-terminus is obscured behind the core of the protein. 
 
 
 
 
Figure 1.6 Overview of the HDAC1 Molecule 
C Terminus 
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1.2.4 Repression of Active NF-κB 
As mentioned previously NF-κB has been well established as a critical and 
potent transcription factor family in terms of the transcription and initiation of both 
acute and chronic inflammation [99]. Therefore, such a system would require and 
equally effective regulator to initiate and maintain the resolution of any 
inflammatory event. While it is known that IκB’s serve as initial cytoplasmic 
inhibitors, very little evidence outlines the fate of NF-κB dimers in the nucleus post-
stimulation. Work which goes against this widely supported dogma of constant 
cytoplasmic sequestration is the growing number of studies that show that dimers 
are not static and that even under resting conditions they are trafficked in and out 
of the nucleus [15]. Nelson et. al. found that the number and amplitude of these 
cycles of phosphorylation, dephosphorylation and degradation had a significant 
impact of genes transcribed [15]. With this in mind a theory could emerge that once 
activated, and gene transcription commences, inhibitors may be transcribed which 
may then enter the nucleus and sequester active dimers to the cytosol once more 
in a negative feedback loop. This is the argument proposed by Arenzana-
Seisdedos et. al. who showed that nuclear IκBα could bind active p65:p50 and 
export it to the cytosol however this has not been widely accepted as the major 
mechanism for inhibition post activation for a number of reasons [100]. 
 IκBα, like other IκB’s, bind active dimers using several of its Ankyrin repeat 
domains and masks the otherwise accessible nuclear localization signals on all NF-
κB subunits. In addition to this, IκBα can disrupt the DNA binding domain of dimers 
such that they are no longer able to bind DNA. Finally, IκBα itself is not usually 
present in the nucleus of cells and other studies which have found small amounts 
of nuclear IκBα were unable to confirm its ability to bind DNA bound active dimers 
[101]. To affect the ablation of response, newly synthesized IκBα would have to be 
first imported, bind active dimers and then exported. While there is some evidence 
in support of this, other mechanisms have been discovered which are becoming 
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more widely accepted as pathways to resolve inflammation including p50:p50 
homodimers [14]. 
1.2.5 Evidence for the p50:p50:HDAC1 Interaction 
Recall, p50 homodimers are thought of as resting state repressors of gene 
activation and through the binding of other co-factors such as CBP and Bcl3 they 
can upregulate anti-inflammatory genes or deny pro-inflammatory gene producing 
dimers access to target promotors [102]. In addition to this passive dimer blockade 
and active anti-inflammatory gene transcription, it is believed that p50 may recruit 
another co-factor to augment the structure of gene promotors and switch off 
transcription in a more permanent active manner through the recruitment of 
HDAC1. Zhong et. al. were the first to show that HDAC1 could bind both p50 and 
p65 and that phosphorylation of the subunit determined its preferred co-factor 
[103]. Since then, Elsharkawy et. al. also found a major role for the p50:p50:HDAC1 
complex in the repression of many traditional pro-inflammatory genes [104]. In 
particular, they found that inhibition of HDAC1’s deacetylase activity mimicked the 
pro-inflammatory phenotype observed in Nfkb1-/- cells. Moreover, Paz-Priel et. al. 
found that C/EBPα was able to displace HDAC1 from p50 homo-dimers that were 
actively repressing anti-apoptotic genes and the removal of this gene repression 
was key in acute myeloid lymphoma [70]. These two cases highlight an important 
role in cancer and immunity and are both continually supported by new evidence. 
In 2015, Wilson et. al. have shown that p50 homo-dimers are critical in neutrophil 
driven hepatocellular carcinoma and also attribute this to their association with 
HDAC1. Their work shows that, in the absence of p50, HDAC1 does not associate 
with the potent neutrophil chemotaxis genes cxcl1 and cxcl2. 
Though this and other evidence makes a strong case for this p50:HDAC1 
interaction, very little structural evidence has been provided thus far. If this 
interaction is as important as the evidence so far suggests, it may be key in 
developing better ways to selectively repress inflammation and may ultimately lead 
to better anti-cancer and anti-inflammatory therapeutics. 
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1.3 Aims 
 
Though some preliminary studies on the interaction between p50 and 
HDAC1 have been reported, little detail about how these two proteins physically 
interact as well as the contribution to homo-dimerization makes has not been 
studied. As such the aims of this project were as follows: 
 
• Understand the role of p50 homo-dimerization in the context as scaffold for 
gene repression. 
• To determine the exact region of p50:HDAC1 interaction and gain insights 
into its possible mode of regulation. 
• To understand the relative importance of active p50:HDAC1 repression of 
NF-κB driven inflammation. 
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Chapter 2 Materials and Methods 
 
2.1 Cell Culture 
Cos-7, U2OS, HeLa, LX-2 and Nfkb1-/- , WT and Nfkb1S340A Murine Embryonic 
Fibroblasts (MEFs) from a C57Bl/6 background were maintained in Dulbecco's 
Modified Eagle Medium (DMEM) (GIBCO) supplemented with 100 U/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine and 10% fetal bovine serum at 37°C at 
an atmosphere of 5% CO2. THP1 cells were maintained in RPMI 1640 (GIBCO) 
supplemented with 100 U/ml penicillin, 100μg/ml streptomycin, 2mM L glutamine 
and 10% fetal bovine serum at 37°C at an atmosphere of 5% CO2. 
2.2 Cell Harvest and Protein Lysate Preparation 
Cells were washed in PBS and then scraped into PBS and harvested by 
centrifugation. Cell pellets were then resuspended in RIPA lysis buffer (150mM 
NaCl, 50mM Tris-HCl pH 7.5, 0.1% SDS, 1% Triton, 0.5% Deoxycholic acid with 
phosphatase and protease inhibitors) on ice at for 20 minutes followed by storage 
at -80°C. 
2.3 Western Blot 
Protein lysate concentration was determined by Bio-Rad Protein Assay Kit as per 
manufacturer’s instructions along with photo spectrometry at a wavelength of 
450nm. 30μg or 50μg of protein was denatured at 95°C for 5 minutes. Total protein 
or immunoprecipitated samples were fractionated by 7–12% SDS-PAGE and 
transferred to nitrocellulose membrane. Blots were blocked with TBS-Tween (0.1% 
TBS-T) containing 5% milk protein before overnight incubation with primary 
antibodies (1 hour at room temperature for HRP conjugates) in either 5% milk TBS-
T or 5% Bovine Serum Albumin (SIGMA). Primary antibodies against (1:1000) p65 
(sc372 Santa Cruz), (1:2000) GAPDH (ab22555 Abcam), (1:1000) p105/p50-HRP 
conjugate (ab195854 Abcam), (1:1000) p105/p50 (Abcam, ab7971), (1:1000 ) 
Sin3A (ab3479 Abcam),  (1:2000) c-Rel (sc71 Santa Cruz) or (1:1000) HDAC1-
HRP conjugate (ab193096 Abcam). Next, membranes were washed in TBS-T and 
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further incubated with (1:1000) HRP-conjugated mouse anti-rabbit IgG (7074S 
CST) for one hour at room temperature. After a final wash antigens were detected 
by chemiluminesence (Amersham Biosciences). 
2.4 Proteasome Inhibition 
Nfkb1-/- , WT and Nfkb1S340A MEFs were serum starved overnight and then treated 
overnight with 10uM MG132 Proteasome Inhibitor (SIGMA) or left untreated and 
lysed in 50μl RIPA lysis buffer for 20 minutes followed by sonication for 5 minutes. 
Protein was then analyzed by western blot. 
2.5 Transient Transfection 
Mammalian expression constructs were transfected into Cos-7, U2OS, HeLa and 
Nfkb1-/- and WT MEF cell lines for an assay dependent time period using Effectene 
Transfection reagent (301427, Qiagen) following manufacturer’s instructions. 
Briefly, cells were seeded to 40-60% confluency and DNA for transfection 
incubated in EC Buffer with Enhancer (1:8) and Effectene reagent (1:10) for 5 and 
10 minutes respectively. This mixture was further diluted in DMEM and added 
dropwise to cells under normal culture conditions for the indicated time period. 
Following incubation, cells were then treated or harvested.  
2.6 Luciferase Assay 
Luciferase assays were performed using a Dual Luciferase Assay Reporter System 
(E1910, Promega) following manufacturer’s instructions. pGL2 reporter plasmids 
containing a 3X κB promotor, IL-6 promotor or IκBα promotor were transfected at 
0.5μg/well in 6 well plates for 24 hours along with either WT p50-Flag, or p50Mu-
Flag at 0.5μg/well as well as a Renillia luciferase reporter construct at 0.05μg/well. 
Relative luminescence was normalized to co-transfected Renilla luciferase, control 
luciferase reporter as well as total protein.  
2.7 Molecular Dynamics Simulations 
Molecular dynamics simulations were carried out on various dimer pairs. In short, 
PDB ID 1NFK (WT p50:p50 homodimer) and 1LE5 (WT p50:p65 heterodimer) 
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along with 1NFK p50S340A chain A and 1LE5 p50:p65p50 were massaged for 
molecular dynamics and topology and coordinate start files generated in both dry 
and TIP3PBOX explicit water, Na+ charge balanced configurations. Using Amber 
force field ff99SB unrestrained molecular dynamics simulation were run to a total 
of 100 ns using the grand canonical ensemble after 100ps of equilibration to 300°K. 
Simulations were carried out on the Polaris SGI High Performance Computing 
Cluster at Leeds University. Data analysis was then carried out with Amber ptraj, 
UCSF Chimera or in R with trajectory visualization in VMD and UCSC Chimera 
[105]. 
2.8 Multiple Sequence Alignment and Evolutionary Analysis 
Amino acid sequence data was gathered from the Ensembl Database by using 
human gene orthologues across all available species and from the Uniprot 
Database by gene ID. Greater than 60 sequences representing evolutionarily 
separated organisms from Homo sapiens to Ciona intestinalis was aligned and 
viewed in JalView using MAFFT with defaults or Clustal W with defaults. 
Alignments were then visualized on 3D crystal structures of the various NF-κB 
subunits using UCSF Chimera and PDB files stored in the Protein Data Bank 
(PDB). Crystal structures used were as follows, 1NFK – p50 Homo-dimer bound to 
a kappaB site [49], 1LE5 – p50:p65 Heterodimer bound to interferon β kappa B site 
[106], 3DO7 – p52:RelB heterodimer bound to kappaB site [107] and 1GJI- c-Rel 
homo-dimer bound to IL-2 response element [29]. 
2.9 Immunofluorescence Microscopy 
2.9.1 Endogenous Immunofluorescence 
U2OS cells were seeded at 40-50% confluency in 4 well chamber slides. Cells were 
then washed with PBS and fixed in 4% formaldehyde followed by permeabilization 
with 1% (v/v) Triton-X and blocked for 1 hour in 5% (w/v) Bovine Serum Albumin 
(BSA). Cells were then incubated over night at 4°C with anti-p105/p50 (Santa Cruz, 
SC114-X) in 5% BSA. Cells were then washed in PBS and incubated for one hour 
with anti-rabbit-IgG-Rhodamine (SAB3700846, Sigma). Cells were then washed in 
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PBS and mounted with ProLong Gold Antifade Mountant with DAPI (P36935, 
Thermo-Fisher) and imaged on a Nikon Inverted Confocal Microscope at 20x. 
2.9.2 Nuclear Localization Immunofluorescence Microscopy 
U2OS cells were seeded at 40-50% confluency in 4 well chamber slides and 
transfected with 0.5μg of either WT p50-FLAG, p50Mu-FLAG or vehicle only and 
incubated for 24 hours. Cells were then washed with PBS and fixed in 4% 
formaldehyde followed by permeabilization with 1% Triton-X and blocked for 1 hour 
in 5% Bovine Serum Albumin (BSA). Cells were then incubated over night at 4° 
with anti-FLAG-FITC antibody (F4049, Sigma) in 5% BSA. Cells were then washed 
in PBS and mounted with ProLong Gold Antifade Mountant with DAPI (P36935, 
Thermo-Fisher) and imaged on a Nikon Inverted Confocal Microscope at 20x. 
2.10 Flag, Endogenous and Co-Immunoprecipitation 
Tissue or cells were washed in PBS and lysed for 20 minutes in Co-IP lysis buffer 
(50mM Tris-HCL pH 7.4, 150mM NaCl, 1mM EDTA and 1% (v/v) Triton-X) with 
fresh protease inhibitors (118735801, Roche). 25μg of lysate was kept as input and 
500μg of lysate was incubated with 2μg of anti-p105/p50 (D7H5M CST), nuclear 
localization specific anti-p50/p105 (sc-114x Santa Cruz), anti-p105/p50 (H119 
Santa Cruz), anti-p65 (sc 372 Santa Cruz), anti-IκBα (L35AS CST), Sin3A (ab3479 
Abcam), anti-Gal 4 (SC 510, Santa Cruz) normal IgG (ab46540-1 Abcam) or anti-
FLAG beads (A2220 Sigma) for 1 hour at 4°C diluted to a total volume of 500μl in 
Wash Buffer (50mM Tris-HCL pH 7.4 and 150mM NaCl). Apart from samples with 
FLAG beads, a 1:1 mix of Protein A and Protein G agarose beads (P6649 and 
P3296 Sigma) were then added to samples and incubated a further hour at 4°C. 
All samples were then washed in Wash Buffer three times and bound complexes 
eluted by boiling with 1X SDS-Loading Dye (0.5% (v/v) SDS, 0.5% (v/v) Glycerol, 
65mM Tris HCl pH 8.1, 2.5% β-mercaptoethanol and trace Bromophenol Blue) at 
95°C or by incubation with Wash Buffer (50mM Tris-HCL pH 7.4 and 150mM NaCl) 
containing excess FLAG peptide (100ug/ml) in the case of FLAG IPs. Samples 
along with inputs were then assessed by Western Blot. 
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2.11 GRAMM-X Protein Interaction Prediction and Visualization 
p50 HDAC1 interaction predictions were performed by the GRAMM-X software for 
ridged body protein-protein interactions [108]. Chain A and B of the available 
crystal structure of the p50 homodimer (PDB:1NFK [49]) were used as a receptor 
molecule for its ligand, chain B of the HDAC1 crystal structure (PDB:4BKX [95]). 
Potential interacting intermolecular hydrogen bonds were calculated using the 
HBond function in UCSC Chimera with relaxed bond constraints of 7Å and 20% 
bond angle flexibility. Structural modelling and images were generated in UCSF 
Chimera [105]. 
2.12 Solvent Accessibility Calculations 
Solvent accessibility for residues were calculated by the POPS algorithm [109] for 
solvent accessible surface areas using crystal structures of each of the NF-κB 
subunits as follows. 1NFK – p50 homo-dimer bound to a κB site [49], 1LE5 – 
p50:p65 heterodimer bound to interferon β κB site [106], 3DO7 – p52:RelB 
heterodimer bound to κB site [107] and 1GJI- c-Rel homo-dimer bound to IL-2 
response element [29] 
2.13 PCR, Hi-Fidelity PCR and DNA Gel Purification 
Standard PCR was carried out using ThermoScientific Dream Taq DNA 
polymerase Master Mix along with 1μl of cDNA and assorted primers at various 
melting temperatures. High fidelity PCR was carried out using ThermoScientific 
Phusion High Fidelity DNA polymerase at 0.02U/μl along with X1 HF Buffer, 200μM 
Nucleotide Mix, or Q5 High Fidelity Polymerase (New England Biolabs) and 0.5μM 
of each forward and reverse primer and 1μl of cDNA. This was made up to 20μl in 
nuclease free water and denatured at 98°C for 30 seconds followed by 35-40 
cycles of 10 seconds denaturation (98°C), 10 seconds annealing (primer specific 
temperature), 30seconds/Kb extension (72°C). This was followed by a final 
extension at 72°C for 10 minutes. Results were then visualized by either Ethidium 
Bromide Gel Electrophoresis or Gel Green Nucleic Acid Stain (Biotium) on 1-2% 
(w/v) agarose gel and imaged under UV light or by Dark Reader Transilluminator 
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(Clare Chemical Research). Utilizing a sterile scalpel, bands of interest were 
excised and DNA purified by QIAquick Gel Extraction Kit (Quiagen). Purified 
samples were quantified by Nanodrop (Thermo). Primers lists can be found in 
Figure 2.1 and 2.2. 
2.14 RNA Isolation, Quantitative Real Time PCR and General PCR 
Conditions 
Total RNA was isolated from cells using an RNeasy Mini Kit (74104, Qiagen) and 
treated with DNAse. Briefly, cells were washed with PBS and lysed directly in 
appropriate amounts of Buffer RLT. This was then mixed with 1 volume of 70% 
ethanol and RNA isolated on an RNeasy Mini spin column after washes with buffer 
RPE. RNA was eluted in RNase-free water and treated with DNAse (Promega) to 
remove any contaminating DNA. This RNA was then used as a template for the 
synthesis of complementary DNA using random primers (Promega). SYBR Green 
quantitative RT-PCR was performed using primers listed in Appendix 7.3 and the 
PCR scheme detailed below in Table 2.1. 
 30-45 cycles   
Initial 
Denaturation 
Denaturation Annealing Elongation Final 
Elongation 
Hold 
95° 1 minute 95°C 30sec Variable 72°C 30sec 72°C 10 
minutes 
4°C 
 
Table 2.1.1 General PCR Cycling conditions used to perform PCR and RT-PCR 
unless otherwise indicated 
2.15 Generation of Mutant p50-FLAG Constructs 
Mutant constructs were all generated from a parent p50-FLAG pcDNA3.1 
backbone kindly provided by N. D. Perkins (Newcastle University) Appendix 7.2. 
Mutations were generated using a Q5 Site Directed Mutagenesis Kit (E0554S, New 
England Biolabs). Briefly, template p50-FLAG pcDNA3.1 was incubated at 95°C 
followed by 3 minute cycles at the appropriate annealing temperate with a final 
incubation at 72°C for 10 minutes. This linear mutant DNA was then circularized 
39 
 
using the KDL enzyme mix at room temperature for 15 minutes and products 
transformed into DH5α competent E.Coli (C2987H, New England Biolabs) and 
colonies selected by antibiotic resistance. Plasmids were then purified using an 
Endotoxin Free Plasmid Maxi Kit (12163, Qiagen). All mutants were confirmed by 
Sanger sequencing (GATC Bio-tech). Primers used in mutagenesis can be found 
in Appendix 7.3. 
2.16 Generation of Chemically-competent DH5α E.coli 
Competent E. coli were generated using the Inoue method as described by A. 
Untergasser with minor amendments [110]. Competent DH5α E. Coli (Invitrogen) 
were grown in an overnight culture of 10ml Luria-Bertani medium (LB) and 5 mls 
used to inoculate two flasks each with 250mls LB. Cell were allowed to grow at 
37°C to an optical density of 0.6 before being placed on ice for 10 minutes. Bacteria 
were then pelleted at 2500g for 10 minutes at 4°C. Pelleted cells were then re-
suspended in 80ml ice cold Inoue Solution (55mM MnCl2, 15mM CaCl2, 250mM 
KCl and 0.01M piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) [Sigma]) then 
re-pelleted at 2500G for 10 minutes at 4°C. Pelleted cells were then re-suspended 
in a final volume of 20mls of Inoue buffer and 1.5 ml DMSO added. 500μl aliquots 
were placed in 1.5ml Eppendorf tubes and flash frozen in liquid nitrogen and stored 
at -80°C for future use. 
2.17 Generation of petM30 protein expression constructs 
Using a petM30 backbone (Appendix 7.1, Gift from Will Stanley NICR Newcastle 
University), various bacterial expression constructs were created to express 
recombinant human p50, p65 and HDAC1 with n-terminal 6xHIS-GST-TEV tags. 
Constructs were created using the Gibson assembly method using the NEB HiFi 
DNA Assembly kit. Briefly, petM30 was linearized using NcoI and HindII and ligated 
to PCR products (primers and annealing conditions found in Appendix 7.4) 
containing full length or fragments of genes of interest along with a 20-25 bp 
overlap of backbone sequence at restriction sites. The cloning regime is covered 
below in Table 2. 
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Table 2.2. Cloning Regime for bacterial expression vectors for recombinant 
protein expression. 
2.18 DNA Ligation, Bacterial Transformation and Protein Expression 
Ligation reactions were set up with gel purified DNA in a 1:3 vector to insert ratio 
with no more than 100ng of total DNA with X1 T4 DNA Ligase Buffer and 20U/μl 
T4 DNA Ligase (New England Biolabs) either overnight or for 2 hours at 16°C. 
Additional ligation reactions for Gibson Assembly Inserts were performed using the 
NEBilder HiFi DNA Assembly Cloning Kit (NEB) as per the manufacturer’s 
instructions into petM30 expression vectors containing both GST and 6x His tags. 
Transformation of competent cells was carried out using either NEB Ultra 
Competent DH5α cells, Rosetta 2(DE3) pLysS Singles Competent Cells 
(Novagen), BL21 DE3 (New England Biolabs), Limo21 (New England Biolabs), 
Tunner (Novagen), Arctic Express (Agilent) or those made as described previously 
(Details in Appendix 7.5). Briefly, 50μl cells were thawed and mixed with 1-100ng 
DNA and incubated on ice for 30 minutes. Cells were then heat shocked at 42°C 
for 45 seconds and placed on ice for 2 minutes. 250μl of SOC (New England 
Biolabs) was used to outgrow cells for 1 hour with shaking at 37°C and 200μl of 
outgrowth spread onto LB plates treated with appropriate antibiotics (100μg/ml 
Ampicillin, 100 μg/ml Carbenicillin, 34 μg/ml Chloramphenicol or 30-50μg/ml 
Kanamycin [Sigma]). Finally, cells were incubated at 37°C overnight and examined 
for colony formation the next morning. Expression was carried out in LB buffered 
to pH 7.4 with 50mM Tris.Cl and 1% glucose, Auto Induction Media (Formedium) 
or TB Media (Formedium). Cells were induced for 16 hours at 25°C with ITPG at a 
final concentration of 1mM (LB and TB only) once cells reached an OD of 0.5. Cells 
Insert Amino Acids  5’ Restriction 
Site 
3’Restriction 
Site 
HDAC1 Full Length 483aa NcoI HindIII 
HDAC1 Fragment 8-378aa NcoI HindIII 
p50 Full Length 435aa NcoI HindIII 
p50 Fragment Length 40-353aa NcoI HindIII 
p65 Fragment Length 20-291aa NcoI HindIII 
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harvested by centrifugation at 25000g were lysozyme treated for 20 minutes and 
sonicated for 5 minutes to liberate protein and analyzed by SDS-PAGE and 
Coomassie Blue Stain. 
2.19 Bacterial DNA MiniPrep, MaxiPrep and Restriction Enzyme 
Digestion 
Bacterial colonies of interest were picked from overnight plate growth and outgrown 
in 10mls LB media. Plasmid DNA was isolated by QIAprep® Spin Miniprep or 
MaxiPrep Kit (Qiagen) following manufacturer’s instructions. Purified DNA was 
quantified using ThermoScientific NanoDrop™ and used for further analysis. 
Restriction DNA digestions were performed using 5ng of DNA and 10U/μl of 
appropriate Enzyme and buffer (New England Biolabs and Promega) in a total 
volume of 20μl of nuclease free water. Reactions were resolved on a 2% agarose 
gel with ethidium bromide and visualized via UV trans-illumination. 
2.20 Protein Purification 
Protein lysates from various bacterial stains were passed through columns loaded 
with HisTrap nickel charged affinity gel (GE) to bind expressed 6X His -tagged 
proteins. Proteins were then eluted in fractions with buffers (50mM NaPO4, 150mM 
NaCl, 10% Glycerol with varying imidazole) containing increasing imidazole 
concentration. Fractions collected were analyzed by SDS-PAGE and Coomassie 
stain to identify expressed proteins. Fractions with high yield were then further 
purified by GST-affinity column chromatography (GE). GST-His6X tags were then 
cleaved from recombinant proteins using in-house purified TEV protease at 4°C 
overnight. After cleavage proteins were again purified via HisTrap affinity and pure 
recombinant protein flow through collected. Purified proteins were then buffer 
exchanged against PBS using dialysis tubing (D9652, Sigma) and stored at -80°C 
for future use. 
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2.21 Coomassie Blue and Silver Stains 
Coomassie Blue stains were performed using SimplyBlue SafeStain (Thermo). 
Proteins fractionated on 9-12% SDS-PAGE Gels were washed with distilled water 
and incubated with SimplyBlue SafeStain for 1 hour at room temperature followed 
by a wash with distilled water until background was sufficiently reduced to visualize 
targets. For silver stains, proteins fractionated on 9-12% SDS-PAGE Gels were 
fixed for 1 hour at room temperature (40% ethanol, 10% acetic acid, 50% H2O). 
Gels were then washed for 30 minutes at room temperature and then sensitized in 
0.02% sodium thiosulphate for 1 minute again washed with water and then 
incubated with 0.1% silver nitrate at 4°C for 20 minutes. Gels were then washed 
and developed in 3% sodium carbonate solution until bands were observed. The 
reaction was the quenched with 5% acetic acid and analyzed. 
2.22 Peptide Arrays 
HDAC1, p50 and alanine substitution peptide arrays were kindly provided by the 
Kiely Lab (University of Limerick) and were generated as previously described 
[111]. Membranes were blocked in 5% Milk TBS-T for one hour followed by 
incubation with anti (1:5000) 6x-His Tag Monoclonal Antibody HRP (R931-25, 
Invitrogen) or anti-p105/p50-HRP conjugate (ab195854 Abcam) for 2 hours at room 
temperature and developed by chemiluminescence (Amersham Biosciences) to 
assess peptide antibody cross reactivity. 6xHis tagged recombinant HDAC1 (14-
838, Millipore) at 5μg/ml in 1% milk TBS-T was then added to p50 arrays and 
generated recombinant p50 to HDAC1 arrays overnight at 4°C followed by TBS-T 
wash and incubation again with the appropriate antibody and detection as 
described (Anti 6x His-HRP or anti p105/p50-HRP). This procedure was also 
performed on the p50 alanine substitution array. Each array assay was performed 
in duplicate. 
2.23 Nuclear and Cytoplasmic Extracts 
U2OS or Nfkb1-/- MEF cells transfected with WT, p50Mu (mutant p50) or vehicle 
were washed with PBS and pellets lysed in cytoplasmic lysis buffer (50mM Tris-
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HCL pH 7.4, 50mM NaCl, 1mM EDTA, protease inhibitors and 0.1% Triton-X) and 
homogenized using a 27G needle. Supernatant was kept as cytoplasmic extract 
and pelleted nuclei were washed in cytoplasmic lysis buffer and resuspended in 
RIPA lysis buffer (150mM NaCl, 50mM Tris-HCl pH 7.5, 0.1% SDS, 1% Triton, 
0.5% Deoxycholic acid with phosphatase and protease inhibitors). Samples were 
then analyzed by western blot. 
2.24 Chromatin Immunoprecipitation (ChIP) 
Briefly, Nfkb1-/- MEFs transfected for 48 hours with WT p50, p50Mu (mutant p50) 
or vehicle only were cross-linked by addition of formalin at 1% final concentration 
for 5 minutes at RT, then quenched with glycine buffer at final concentration of 125 
mM. The cells were rinsed in cold PBS, and harvested into PBS with protease 
inhibitors and centrifuged for 5 min, 4°C, 1,000g. The pellet was resuspended in 
ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH8.1) and incubated for 
20 min on ice. Lysate was sonicated to generate average size fragments of 200-
700bp; cell debris was pelleted by centrifugation for 10 min, 4°C, 8,000 x g. 25 μg 
of chromatin per IP was diluted 1:10 with dilution buffer (1.1% Triton, 1.2mM EDTA, 
16.7mM TRIS-HCl pH8.1,167mM NaCl, with protease inhibitors) and precleared by 
incubating with 25 μl blocked Staph A membranes (Sigma, P7155) for 15 minutes. 
Pre-cleared chromatin was then incubated with 5 μg anti-acetyl H3 (ab47915, 
Abcam), anti-p50/p105 (ab7971, Abcam)  or irrelevant IgG (ab171870, Abcam) 
overnight at 4°C. Immunoprecipitated chromatin was collected with blocked Staph 
A membranes, which were then sequentially washed with cold buffers; Low Salt 
Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 
150 mM NaCl), High Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
20 mM Tris-HCl pH 8.0, 500 mM NaCl), LiCl Wash Buffer (0.25 M LiCl, 1% NP-40, 
1% Sodium Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0) and two washes 
in TE Buffer (10 mM Tris pH 8.0, 1 mM EDTA). The immunoprecipitated chromatin 
was eluted in 500 μl Elution buffer (1% SDS,100mM NaHCO3), cross-links 
reversed and DNA obtained by phenol:chloroform extraction and gel purification. 
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The level of cxcl1 and cxcl2 gene promoter association with acetylated H3 were 
quantitatively measured by real-time PCR using primers listed in Appendix 7.3. 
2.25 TNFα Treatment 
Cells were treated with recombinant TNFα (300-01A, Peprotech) for 1, 3 or 6 hours 
at a final concentration of 10ng/ml in specified cell culture media. 
2.26 Enzyme Linked Immunosorbent Assay 
Enzyme Linked Immunosorbent Assay Mouse IL-6 DuoSet (DY406, R&D Systems) 
was used to quantify total mouse IL-6 in supernatant of Nfkb1-/- MEFs transfected 
with vehicle, WT or p50Mu for 18 hours followed by treatment with or without TNFα 
(10ng/ml) for 6 hours. This sandwich ELISA was performed as per manufactures 
instruction. Briefly, diluted capture antibody was used to coat a 96-well microplate 
at room temperature overnight. After three washes (PBS) plates were blocked in 
reagent diluent (provided) for one hour at room temperature. After three PBS 
washes 100ul of sample or standards were added to appropriate wells and 
incubated at room temperature for 2 hours. After three PBS washes diluted 
detection antibody was added for 2 hours at room temperature. After washes 100ul 
streptavidin-HRP working solution was added to wells for 20 minutes followed by 
a final wash and the addition of 100ul substrate solution in the dark for 20 minutes. 
50ul of stop solution was then added and plates read and 450nM and well as 
570nM for optical correction and analyzed against standards. 
2.27 Neutrophil Isolation and Chemotaxis Assay 
Bone marrow derived neutrophils were isolated from the femur and tibia of C57BL/6 
WT mice by flushing HBSS (Hanks' Balanced Salt Solution, Sigma) supplemented 
with 20mM HEPES and 0.5% (v/v) fetal calf serum. Red blood cells were lysed with 
BD PharmLyse buffer (BD Biosciences; Ref: 555899) and cellular debris removed 
using a 40μm filter. Neutrophils were isolated by negative depletion of non-target 
cells through magnetic-labelling and column separation (Neutrophil Isolation Kit - 
Mouse, Miltenyi Biotec; Ref: 130-097-658). Isolated neutrophils were then added 
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to 3μm inserts in complete DMEM which were inserted into wells containing media 
from Nfkb1-/- MEFs reconstituted with WT p50, p50Mu, vehicle controls or 
unconditioned media only with or without TNFα. After 2 hours neutrophils that 
migrated into the lower chamber were stained with trypan blue and counted by 
haemocytometer. Chemotaxis was performed in triplicate with n=3 conditioned 
media. 
2.28 Statistical Analysis 
Data are expressed as mean ± standard error. Microsoft Excel was used to perform 
unpaired Students T-test and one-way ANOVA and *p<0.05, **p<0.01 or 
***p<0.001 was considered significant. 
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Chapter 3 p50 Dimerization: Residues Critical to p50 
Stability and Partner Selection 
 
3.1 Introduction 
 
It is well established that NF-κB subunits carry out their role as activators 
and repressors of transcription in the form of dimers which differentially regulate 
gene expression in a partner dependent manner [99]. As mentioned previously, 
however, the stage at which dimer partner selection occurs remains unclear. 
Current dogma assumes that cytoplasmic inhibited pre-formed dimers are released 
based on specific inhibitor degradation by the appropriate stimuli and these free 
dimers are then able to undergo nuclear import with the assistance of molecules 
such as importin [112]. This would imply that all possible dimer combinations exist 
in resting cells but shed no light on the ability of dimers to swap partners upon 
activation. This lack of understanding is also compounded by the fact that the 
degree of compensation between dimer combinations is poorly characterized. In 
particular, the differential binding of p65:p50 heterodimers and p65 homodimers 
has been technically difficult to elucidate. Work by Sengchanthalangsy et. al. 
showed that differences in the dimerization domains of p50 and p65 seemed to 
account for some of the observed affinity differences between p50 and p65 homo 
and heterodimers. Their work suggested that mutation in these distinct residues 
were partially responsible for dimer affinity though they note a major drawback of 
their study was that it was performed in the presence of the mutation in both 
partners of the dimers tested [113]. Moreover, several studies have shown that 
mutations outside of the dimerization domain can have major implications on dimer 
formation [4,58,114].  
Ganchi et al. found that mutations of C216 to alanine caused a disruption of 
p65’s ability to form homodimers [115]. Moreover, non-interface residues are 
responsible for the unique binding nature of RelB dimerization as discussed 
previously [115]. It has also been discovered that p50 homo-dimerization is greatly 
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influenced by mutation at serine 343 (human). Wilson et al. report that p50 S340A 
(mouse) mutants are completely unable to form homodimers, though heterodimers 
are unaffected [58]. Notwithstanding these alternative methods for dimer control, 
previous studies have identified a hierarchy of affinities for NF-κB dimers where 
p50:p65 > p50:p50 > p65:p65 [116]. While this hierarchy relates to dimer formation 
affinities other studies have shown that p50 homodimers in some instances bind 
target DNA more strongly than its p50:p65 heterodimer counterpart [117]. This was 
generally dependent on the consensus site being observed but raised the question 
of whether or not the key regulatory mechanism for the deactivation of NF-κB 
signaling is through some form of dimer swapping or replacement regime [118].  
Current theories surrounding post stimulation switch off of NF-κB signaling 
are in general poorly understood when compared with NF-κB activation. As 
mentioned previously, one method through which signaling may terminate is 
through the ubiquitin mediated proteasomal degradation of subunits. Subunits 
which are active for prolonged period will, without protection, become subject to 
poly-ubiquitination and are degraded, removing them from the pool of active NF-
κB. Much of the specifics of this mechanism is poorly characterized but Collins et. 
al. have documented a case for BCL-3 acting as a guard against p50 homodimer 
poly ubiquitination. In light of these finding, understanding factors which contribute 
to the internal and environment mediated stability of subunits becomes vital in 
understanding their ability to associate with their selected partners. Additionally, it 
is thought that a combination of post-translational modifications to active dimers as 
well as the negative feedback loop generated by the transcription of IκB eventually 
switch off the signal but finer details are elusive. Nevertheless, as it relates to p50 
homodimers, one could hypothesize that, in the context of binding sites for which 
it has higher affinity, p50 homodimers may both blockade active p50:p65 
heterodimers or  assist in the termination of signal by displacement of p50:p65 from 
promotors. To in anyway validate this theory, a much better understanding of how 
homodimers are formed and controlled is needed. In turn, understanding the 
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formation and potential for displacement of ‘active’ signaling subunits will further 
elucidate the functions of a potential p50:HDAC1 co-repressor. 
 
 
3.2 Aims 
Given the poor understanding of p50 and p65 dimerization affinities in the 
context of residue specific contribution the aims of this chapter are as follows: 
 
• To determine the mechanism by which p50 S343 mutation disrupts p50 homo-
dimerization. 
 
• To investigate all possible unique residues that could lead to preferential 
dimerization in the context of evolutionary conservation in p50 and p65. 
 
• To determine the contribution of conserved structural differences between p50 
and p65 and their effects on p50 homodimer formation. 
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3.3 Results 
3.3.1 Phosphorylation of p50 S343 as a master regulator of p50 homo-
dimerization 
Few studies in the literature have addressed the unknowns surrounding 
dimer selection in the NF-κB field. However, it has been shown that dimerization of 
p50 homodimers, but not p50:p65 heterodimers is affected by a serine to alanine 
mutation at serine 343 (340 in mouse). Due to the nature of this site, an accessible 
serine residue, it is quite possible that a phosphorylation event here could be a 
master regulator of p50 dimerization. Whatever the mechanism of its homodimer 
prevention, Wilson et. al. showed that loss of p50 homodimers as a result of p50 
S343A mutation recapitulated the pro-inflammatory phenotype observed in p50 
knock out mice [58]. Therefore, whether it is through dynamic control of p50 dimers 
through phosphorylation or some other mechanism, this site warranted further 
investigation. As such I set out to investigate the role of S343 in the control of p50 
homodimers, specifically, its role in dimer stabilization. 
 As seen in Figure 3.1, serine 340 (the mouse equivalent of human serine 
343) occupies a region at the far C-terminal of p50 and is on the opposite side of 
the dimerization domain of the rel homology region of p50. This positioning grants 
solvent access to the residue and due to the flexible nature of p50 (two globular 
domains tethered by a single unstructured linker), it is therefore not hard to imagine 
that this residue is a candidate for phosphorylation. As a result attempts were made 
to detect phosphorylation at this site in both endogenous p50 as well as generated 
recombinant protein (see chapter 4). Antibodies raised against phosphorylated p50 
S340 were used to probe cell and tissue lysates from mouse and human sources, 
however, a clear signal that provided confidence was not obtained by western blot. 
Additionally, samples from immuno-precipitated endogenous p50 as well as 
recombinant generated p50 (discussed in Chapter 4) did not yield convincing 
evidence for p50 S340 phosphorylation by mass spectrometry.  Issues with these 
mass spectrometry experiments arose from the detection of p50 peptides and it 
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Figure 3.1 Crystal Structure of a p50 Homodimer. 
Structural model of a mouse p50 homodimer bound to κB site highlighting the 
location of Serine 340 on an external loop of the Dimerization Domain of the rel 
homology region (RHR). Residues which facilitate DNA binding are also 
highlighted in the DNA binding domain. Rendered in UCSF Chimera with 
rounded ribbons. Blue indicates base pairs of DNA with red phosphate sugar 
backbones. 
 
N Terminus 
C Terminus 
C Terminus 
N Terminus 
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did not rule out or support a phosphorylation event at this residue on p50. Further 
evidence for a potential phosphorylation event at p50 S340 is supported by 
previous data from our lab and others which show that serine 381, the equivalent 
residue on p65, is indeed phosphorylated.   
Having a known homologous phosphorylation site on p65, all possible 
phospho-residues in this region of p50 were compared to all other NF-κB subunits. 
Additionally, as it would be useful in clarifying the complexity involved in dimer 
selection at the structural level in relation to p50, in depth sequence analysis 
through evolution on the five subunits of the NF-κB family was performed. 
Sequences were derived from the reference genomes of 56 organisms spanning 
the evolutionary spectrum from drosophila to humans. The longest protein coding 
transcript was used per species and full list can be found in Figure 3.2. Multiple 
sequence alignments were carried out within each of the five-member subunits on 
56 species including the known orthologues of the genes if a direct gene 
comparison was not possible. These multiple sequence alignments were then 
analyzed for sites of conservation between species and between subunits at key 
residues. Seen in Figure 3.3, alignment of consensus sequences of p65 and p50 
with other subunits showed a high degree of conservation between all subunits and 
through evolution at serine 340 (p50)/ 281(p65). Another site of interest that arose 
from this analysis is S276 in p65 which is conserved in p50 (S355) and a known 
phosphorylation site in both proteins [23]. Figure 3.4A also highlights that that both 
of these residues (p65 281 and 276) exist at similar point in three-dimensional 
space of the crystal structure of p65 and match well with the positions of the 
equivalent p50 residues on the p50 crystal structure. Figure 3.4B also shows that 
residue conservation at S276 is high in p65 and its equivalent residues in p50 and 
c-Rel. Moreover, conservation at p65 S281 and equivalent residues is even higher 
and suggests an important conserved role for this residue in NF-κB function. 
Nevertheless, solvent accessibility analysis of the available crystal structures does  
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Phylogenetic tree of all organisms used in the evolutionary multiple sequence alignment 
analysis of all five NF-κB subunits. Organisms are presented in the format: 
Genus/#Nucleotides in the p50 orthologue Species (Common Name) 
 
 
 Figure 3.2 Phylogenetic Tree of Species Used in Evolutionary Multiple Sequence 
Alignments. 
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Multiple sequence alignment of residues on the external surface of the dimerization 
domain of all subunits. Residues with previously determined phosphorylation events in at 
least one residue or nearby residues which may be phosphorylated are highlighted. 
Consensus sequences are labeled based on the positions in mouse p65. 
 
 
 
Mouse p50 Positions 
S340 S335 F327 N219 
Figure 3.3 Evolutionary Multiple Sequence Alignment of Serine Residues 
near Serine 340 (Human S343). 
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Figure 3.4 Serine Residues 
near S340 (Mouse) and 
their Relative Accessibility 
 
 
 
 
 
A. Crystal structure of 
p50:p65 heterodimer 
highlighting the positions of 
potential phosphoserines on 
both proteins.        B. Analysis 
of residues by percent 
conservation through 
evolution by plotting the 
percentage occupancy for a 
particular residue at a given 
location on a given subunit.                             
C. Predicted solvent 
accessibility based on the 
POPS algorithm for solvent 
accessibility of residues 
investigated [109].  
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indicate that S281 is less accessible than S276, though as mentioned previously 
these residues are located in highly flexible regions of the protein (Figure 3.4C).
 While direct evidence of a phosphorylation event at p50 S343 could not be 
determined by mass spectrometry or western blot with antibodies raised against 
phospo-S343 peptides, circumstantial evidence presented here and in previously 
published work which describe the deleterious effects of p50 S343A mutations 
strongly suggest that p50 is indeed phosphorylated at this residue [58]. 
Additionally, this phosphorylation event could have major impacts on the function 
of p50 and could be the main regulatory site which determines the switch between 
p50 homodimer repressors and active p65:p50 heterodimers. Regardless, more 
evidence is required to confirm these assertions and warrants an in depth 
investigation in its own right. 
3.3.2 Serine 343 of p50 is critical for protein stability 
 During the course of experiments used to confirm loss of homodimerization 
of p50 as well as expression in transgenic mice which express p50 S343A, it was 
observed that there was reduced expression of this mutant p50 compared to wild 
type. Indeed, as compared to wild type murine embryonic fibroblasts (MEFs), p50 
S343A MEF’s showed a huge reduction in p50 expression (Figure 3.5A). However, 
it was unclear whether there was suppression of p50 expression or if p50 was 
somehow being degraded in an aberrant way that lead to loss of protein observed 
in resting cells. Previous work in the lab has shown that p50 transcripts in p50 
S340A mice appear at levels comparable to wild type p50 (data not shown). As 
such this leads one to believe that p50 S340A was leading to some form of 
premature, constant p50 degradation. To test this p50 wild type and knock out 
MEFs were transformed with equal amounts either wild type or p50 S340A 
expressing adenovirus. Figure 3.5B shows, however, that overexpressed p50 
S340A was observed at lower levels of expression compared to its wild type 
counterpart.  
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 This observed difference in p50 expression within the same constructs lead 
us to believe that p50 S340A was having a profound effect on the stability of the 
protein in resting conditions leading to degradation. Initially it was thought that this 
ineffective p50 was simply being recycled since it was unable to form homodimers 
in resting cells. To show this p50 S340A, wild type and p50 knock out MEFs were 
left untreated or treated with proteasome inhibitor mg132 for 6 hours. The rationale 
for this experiment being that unstable p50 S340A would accumulate to levels 
comparable to wild type showing a proteasome mediated degradation of p50 which 
was unable to carry out its normal function. Surprisingly, p50 S340A still showed 
reduced levels of protein compared to wild type p50 even after proteasome 
inhibition (Figure 3.5C). This finding was a bit perplexing as it meant that either our 
initial assumption that p50 S340A did not affect protein production (RNA transcript 
generation and translation) was incorrect or p50 S340A degradation was occurring 
independent of the proteasome.  
To try and tease apart these different theories in silico analysis of the crystal 
structure of p50 was used to create a better understanding of the contribution of 
p50 S340A both locally and to the structure of p50 as a whole. To do this I 
collaborated with Dr. Sarah Harris in The Astbury Centre for Structural Molecular 
Biology at Leeds University. Together, we were able to perform molecular 
dynamics simulations on available crystal structures to ascertain the overall 
contribution made to the stability of p50 by the serine 340 residue. All calculations 
were performed on Polaris, the high performance computer cluster operated by the 
N8 HPC collaboration. Using the amber package for molecular dynamics 
simulations and the available crystal structure of a p50 homodimer (PDB ID: 
1NFK), I performed unrestrained molecular dynamics simulations on a wild type 
p50 homodimer, a p50 homodimer in which one molecule of p50 carried the p50 
S340A mutant and a p50:p65 heterodimer (PDB ID: 1LE5). Residues in the crystal 
structures were first converted to amber format and disulphide bridges conserved. 
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A. 
Western blot analysis of p50S340A, WT and nfkb1-/- (KO) MEF extracts to determine basil 
expression levels of p50 protein in the various cells. Wild type MEFs contained nominal 
levels of p50 while in KO cells p50 levels were undetectable as expected. p50S340A MEFs 
however showed a sever reduction in to p50 expression. B. Western blot analysis of WT 
and nfkb1-/- MEFs reconstituted with either WT or p50S340A through adenoviral delivery. 
After over expression with an adenoviral expression vector p50S340A was present in lower 
levels compared to the WT protein in the same expression vector. C. Western blot analysis 
of p50S340A, WT and nfkb1-/- (KO) MEFs treated for 6 hours with proteasome inhibitor 
mg132. p50 levels remain exceedingly low in cells which have had their proteasome 
inhibited. GAPDH was probed in all blots as loading control to ensure comparable levels 
of protein.  
 
Figure 3.5 Western Blot Analysis of p50 S340A (Mouse) Expression 
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Molecules were then charge balanced with sodium chloride and hydrated with 
explicit water molecules (Figure 3.6A and B). This process was performed for all 
three structures mentioned previously and then slowly raised to a temperature of 
300 degrees Kelvin and allowed to proceed through an unrestrained simulation up 
to 100ns in length. Figure 3.6C shows the representative metrics of a 
p50wt:p50S340A homodimer throughout the first 25ns of its full simulation 
including the protein’s total Root Mean Square Deviation (RMSD) of atoms of the 
entire molecule. Interestingly, when observed at the residue level, alanine 340 (of 
the p50 S340A mutant structure) had almost twice the average RMSD of the wild 
type serine residue in the same crystal structure dimer (A340=4 Å vs. S340=2 Å). 
This finding suggests that the S340A mutation on p50 is having a profound effect 
on the local structural flexibility and potentially stability of this region of the protein. 
In an attempt to determine if this local effect in any way translated to the 
protein as a whole, complete 100ns simulations of a wild type p50 homodimer, wild 
type p65:p50 heterodimer and the mutant S340A p50 wild type p50 homodimer 
were all compared per residue by average RMSD over the full length simulation; 
termed atomic flux. As shown in Figure 3.7, wild type p50:p65 heterodimers show 
the highest degree of divergence from the p50 homodimer simulations which is 
unsurprising given that half of the residues in the simulation are p65 in origin. When 
wild type p50 homodimers are compared to their single chain mutant counterparts 
however, several insightful observations can be made. First, the amino acids in the 
wild type chain (amino acids 1-311) of the p50:p50S340A homodimer appear to 
roughly follow the atomic deviation found in the wild type p50 homodimer, 
especially near residues 135- 200. This region corresponds to the N-terminus of 
p50 which does not participate in dimer formation. Residues corresponding to the 
mutant chain of p50:p50S340A (312-622) however, show much greater divergence 
from the wild chain of the wild type p50 homodimer. With the exception of a few 
points along the protein, p50 S340A mutant chain show substantially  
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A. Initial atomic positions of a p50 WT: p50S340A heterodimer bound to DNA and charge 
balanced by chloride ions (purple). B. Implicit water box surrounding the complex in which 
molecular dynamics simulations were performed. C. Quality control graphs indicating the 
integrity of the simulation as well as analysis of the Root Mean Squared Deviation (RMSD) 
of both Serine 340 and Alanine 340 in their respective chains to determine their positional 
stability during the simulation. 
Figure 3.6 Molecular Dynamics Simulation of p50:p50S340A Homodimer 
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higher atomic fluctuations than its wild type counterpart and in general the dimers 
diverge overall. 
While on its own this study has a few drawbacks, most evidently the fact that 
crystal structures are not complete, it provides more evidence for the 
destabilization of the p50 homodimer by S340A mutation. Moreover, the direct 
comparison between dimers with the only difference being this change in one 
residue highlight the potential regulatory importance of the residue and warrants 
further study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
 
Comparison of atomic flux of three separate molecular dynamics simulations by residue 
number showing greater flux (less stability) in mutated p50 homodimer (p50:p50S340A) 
compared to WT (p50:p50). 
 
 
 
 
 
 
Figure 3.7 Relative Atomic Flux of a p50:p50S340A Molecular Dynamic 
Simulation 
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3.3.3 p50 Dimerization: Evolutionary Insights into Dimer Selection 
In addition to the stability of subunit dimers imparted by phosphorylation, little 
has been uncovered regarding the structural basis of NF-κB dimerization. Having 
generated a library of sequence alignments (see Section 3.3.1) for all subunits 
across species and evolution it was decided to investigate whether this library could 
highlight residues in the dimer interface that could be critical in dimerization and 
therefore conserved. To better visualize these results, multiple sequence 
alignments for each subunit through evolution was mapped onto the respective 
crystal structures available for each subunit and each residue colored by 
percentage conservation. Figure 3.8 confirms the well-known conservation in the 
NF-κB family, especially as it relates to p65 which displays <90% conservation of 
many residues present in the crystal structure; particularly those responsible for 
dimerization and DNA contacts [99]. p50, as well as the other subunits, also show 
a high degree of conservation in the core rel homology region. With this high degree 
of conservation within the subunits I decided to also look at conservation between 
subunits to gain insights into the differences between residues which confer subtle 
subunit specific changes. Of particular importance was the residues involved in 
dimerization and their contribution to dimer selection. As seen in Figure 3.9, a 
number of residues are conserved between p50 and all other subunits when the 
p50 evolutionary multiple sequence alignment is compared that of the aggregated 
evolutionary alignments of all other subunits.  Of particular importance however is 
the comparison between the evolutionary alignments of p50 compared to that of 
p65 as differences in the dimerization domain here would be responsible for any 
observed differential binding. It would not be unreasonable to assume that different 
residues in regions that would make direct contacts between subunits in the p50 
homodimer and p50:p65 heterodimer would have an effect on their binding affinity 
and may make a significant contribution to dimer selection upstream of activation. 
 Once the comparison between p50 and p65 was performed and visualized 
on the crystal structure of p50 it was noted that four residues in the dimerization  
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A-E. Percentage conservation of each subunit mapped onto the available crystal 
structure. Data derived from evolutionary alignments from species listed in Figure 3.2. 
Alignments visualized in UCSF Chimera. 
 
 
Figure 3.8 Evolutionary Analysis of all NF-κB Subunits relative to their Respective 
Crystal Structures 
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Percentage conservation of residues in p50 compared with conserved residues in all other 
NF-κB subunits (left) or conserved residues in p65 (right). Alignments visualized in UCSF 
Chimera. 
 
 
 
 
Figure 3.9 Evolutionary Comparison of p50 and all other subunits and p50 against 
p65 
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domain differed between p50 and p65. With the exception of these four, all other 
residues that make contact between the two subunits were highly conserved. 
These four residues are highlighted in Figure 3.10 and consist of methionine 253, 
asparagine 254, tyrosine 267 and phenylalanine 307 in mouse p50. These four 
residues appear to participate solely in subunit dimerization, however it was 
observed that P307 in p50 and its counterpart V248 in p65 have the potential to 
form hydrogen bonds with the nearby backbone of the DNA helix. Based on this 
better molecular understanding of subunit dimerization I decided to investigate 
whether these residue differences played a major role in the dimer selection 
process between p50 and p65. More specifically it was important to determine if 
these residues impart more or less dimer stability in the context of the full crystal 
structure. As such an experimental plan was made to use further molecular 
dynamics simulations to interrogate the contributions of these four residues 
collectively. 
 In order to fully appreciate the contributions of these residues collectively, 
three distinct simulations were performed under conditions previously described. 
As a basis of comparison, previously mentioned wild type p50 homodimers and 
wild type p50:p65 heterodimers were used. Additionally, a separate simulation was 
performed on a p50:p50 homodimer in which four residues in one of the p50 chains 
were mutated to those occurring in p65 at the same locations in the protein-protein 
interface. Atomistic data was compared for these three simulations over 100ns. 
Metrics for these experiments can be found In Figure 3.11-13 which show that 
conditions of temperature and total energy per simulation were comparable 
throughout. Given that these simulations were carried out in the presence of DNA 
and that the wild type p50 homodimer and p50:p65 heterodimer were also 
examined, it was hypothesized that an interface change such that a p50 
homodimer acquired a p65:p50 interface would lead to further protein-protein 
instability or stabilization. To measure these effects whole molecule RMSD was 
again employed. 
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A. Crystal Structure of a 
p50:p65 heterodimer 
with evolutionary distinct 
interface residues 
highlighted (red). 
B. Side on view of 
labeled distinct interface 
residues in p50 and p65. 
C. Table of conserved 
residues and their 
counterparts in p50 or 
p65 structure. 
Figure 3.10 Dimerization 
Residues which differ 
between p50 and p65 
through evolution 
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Figure 3.11 Metrics for a Wild 
Type p50 homodimer Molecular 
Dynamics Simulation 
Quality control graphs indicating 
the integrity of a molecular 
dynamics simulation performed 
on a p50 homodimer bound to 
DNA. A. Increasing temperature 
during the initiation phase of the 
simulation graphed to show a 
gradual increase in two steps up 
to a run temperature of 300K. B. 
Temperature graphed over a 
longer period of time which 
shows a stable temperature is 
maintained for the duration of 
the simulation. C. Plot of 
potential, kinetic and total 
energy of the system ensuring 
system stability for the duration 
of the simulation. 
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Figure 3.12 Metrics for a wild 
type p50:p65 Heterodimer 
Molecular Dynamics 
Simulation 
Quality control graphs 
indicating the integrity of a 
molecular dynamics 
simulation performed on a 
p50:p65 heterodimer bound 
to DNA. A. Increasing 
temperature during the 
initiation phase of the 
simulation graphed to show 
a gradual increase in two 
steps up to a run 
temperature of 300K. B. 
Temperature graphed over 
a longer period of time 
which shows a stable 
temperature is maintained 
for the duration of the 
simulation. C. Plot of 
potential, kinetic and total 
energy of the system 
ensuring system stability for 
the duration of the 
simulation. 
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Quality control graphs 
indicating the integrity of 
a molecular dynamics 
simulation performed on 
a homodimer of p50 in 
which one subunit of the 
dimer has been mutated 
to conform to p65 
evolutionarily conserved 
interface. A. Increasing 
temperature during the 
initiation phase of the 
simulation graphed to 
show a gradual increase 
in two steps up to a run 
temperature of 300K. B. 
Temperature graphed 
over a longer period of 
time which shows a 
stable temperature is 
maintained for the 
duration of the 
simulation. C. Plot of 
potential, kinetic and 
total energy of the 
system ensuring system 
stability for the duration 
of the simulation. 
Figure 3.13 Metrics for 
a p50;p50p65 Mutant 
Heterodimer Molecular 
Dynamics Simulation 
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  Using wild type p50 homodimers as a base line it is seen that, overall, 
p50:65 heterodimers form a less stable interaction. However, upon mutation of one 
of the p50 molecules in a p50 homodimer to an interface of p65 average RMSD of 
this mutant dimer falls to below that of a p50 homodimer. Shown in Figure 3.14, 
this analysis suggests that, in the presence of DNA, p50 homodimers exist in a 
more stable confirmation though this can be enhanced by changing dimerization 
critical residues to those that are p65 specific. 
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RMSD comparison of three molecular dynamics simulations performed on a wild type p50 
homodimer, wild type p50:p65 heterodimer and a dimer composing of wild type p50 and 
a molecule of p50 where residues have been mutated to those conserved in p65. (Amino 
acid changes include F307V, Y267F, D254N, M253V) All simulations were run under the 
same initial and maintenance conditions. 
 
 
 
 
 
 
 
 
Figure 3.14 Comparison of wild type p50 homodimers and p65 heterodimers 
against a mutant p50 homodimer which contains a p65 interface in one chain. 
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3.4 Discussion  
Dimer selection and rearrangement remains one of the least understood 
areas of wider NF-κB research. In particular, the rules governing the formation of 
repressive p50 homodimers versus canonical p50:p65 heterodimers which go on 
to activate gene transcription have been poorly characterized. Data presented here 
may be interpreted to support three different views on how this dimer selection/ 
assembly may be carried out in cells. Firstly, dimer selection could be the result of 
post-translational changes carried out directly on subunits and determined by 
numerous signaling events in the cell. Second, evolutionary variation between 
subunits orchestrates a complex order of binding affinities which, over the course 
of a signaling event, lead to the appropriate proportions of active dimers which 
produce the desired result. The third and mostly likely scenario is some 
combination of the previous where numerous factors including modification events, 
specific subunit binding propensities as well as third party interactions all work in 
unison to achieve the desired outcome.  While this would be the most elegant 
solution to understanding this issue of dimer selection, it makes interrogating the 
system a complex undertaking. 
3.4.1 Post-Translational Modification as a Mechanism for Dimer 
Selection 
Discussed previously, numerous sites of post-translational modification have 
been described on NF-κB subunits with wide ranging effects. As it related to 
dimerization, single amino acid modifications have been shown to augment correct 
dimerization. Jacque et al. found that phosphorylation on serine 276 of p65 
encourages dimerization with RelB though it is unclear how it achieves this as it is 
not an interface residue [119]. One argument they propose is that an increased 
negative charge here may be having wide ranging effect on direct interface 
residues. A similar effect may be the cause of the observation that phosphorylation 
at serine 343 (human) may orchestrate a shift to repressive homodimers away from 
a more stable p50:p65 heterodimer. Evidence presented here however, suggests 
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that serine 343 of p50 is playing a larger role than dimer selection and is directly 
contributing to the overall stability of the protein in all observed dimer combinations. 
Given that percentage conservation at this site is near 100% in all subunits (Figure 
3.3B), subsequent observations of the severe loss of protein expression/stability 
are not surprising. Moreover, the increase in flexibility described by a doubling of 
RMSD at the same residue with an S343A mutant (Figure 3.5C) and the overall 
sharp increase in the atomic flux of the subunit as a whole which contains an S343A 
mutant (Figure 3.6) all point to a residue critical to protein integrity. While these 
observations relating to stability are all performed in silico, they conform to the 
observed reduction in protein expression though cannot be used to claim with 
certainty that stability is the sole function of this residue. Further in vitro 
experiments are need to more finely tune our understanding of this residue’s role 
in dimer assembly and structural integrity. 
3.4.2 Evolutionary Distinctiveness as the Major Control Mechanism of 
Dimer Assembly 
 
In addition to post-translational modification of subunits as a mechanism to 
account for dimer selection, observed evolutionary differences in interface residues 
must, in some part, contribute to dimer affinity. Indeed, Huxford and Ghosh discuss 
the known differences between p50 and p65, namely the Y269F and D256N 
substitutions [120]. They go on to explain that Y269 in p50 makes a significant 
contribution to the stability of the p50 homo and heterodimer and its substitution to 
phenylalanine in p65 accounts for the reduced binding affinity in p65 homodimers. 
Evolutionary analysis presented here, however, adds two other residues to the list 
of conserved differences noted in the dimerization interface p50 and p65 (Figure 
3.10). While Huang et al. found that p50 heterodimers are more stable than their 
homodimer counterpart, it has been difficult to measure this difference accurately 
[116]. Presented here, molecular dynamics simulations on wild type and mutant 
versions of hetero and homodimers may help to resolve many of these dimer 
related assumptions. In Figure 3.13 it can be seen that stability (measured by 
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proxy through RMSD) is greatest in a dimer composed of wild type p50 and mutant 
p50 where four interface residues are substituted for those found in p65 (p50p65). 
This simulation, performed in the context of bound DNA does however calculate 
the stability of a p50 homodimer to be greater than that of a p65:p50 heterodimer. 
As mentioned previously, however, dimer stability depends heavily on DNA 
interactions as well as interface differences which could account for this 
observation. Nevertheless, the fact that this combination of wild type and mutant 
p50p65 dimers appear to be the most stable configuration and strongly suggests 
that dimer interface residues make up a major part of the decisions related to dimer 
assembly. The difficulty remains, however, in understanding to what degree these 
dimer interface residues contribute to dimer selection. Specifically, is there a 
pattern of mutation that could be achieved in which dimers of a specific type are 
always preferred? There is likely far more complexity as there is also the know 
contribution of co-factors to dimer choice. 
3.4.3 Co-factors, Post-translational Modifications and Evolutionary 
Differences: The complexity of dimerization. 
Presented here are two methods by which dimerization may be regulated in 
the NF-κB family however the true complex signaling involved in dimerization and 
functional outputs of signaling cascades will depend on numerous factors. Aside 
from obvious tissue and cell specific differences, dimerization has also been shown 
by others to be, in part, regulated by the IκB’s as well. Tsui et al. showed that IκBβ 
was able to encourage the formation of the lower affinity p65 homodimer [121]. 
This study suggests that regardless of innate affinity as determined by interface 
residues conserved through evolution, dimerization of a certain regime may be 
augmented by a tertiary binding partner. In support of this Ashkenazi et. al. found 
that withaferin A, a small molecule inhibitor, was able to allosterically inhibit p65 
dimerization [122]. These two cases reflect the complexity of control that may be 
at play when considering dimerization in any context. This area still needs far more 
investigation into both general control as well as in specific contexts such as under 
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resting and stimulated conditions as well as during resolution of a response. 
Findings presented in this chapter strongly suggest that when considering 
manipulation of NF-κB dimers several precautions are needed. Direct modifications 
of residues that disrupt a specific dimer may have catastrophic impact on the ability 
of that subunit to carry out other functions as well as maintain expression at 
appropriate levels.  Additionally, while evolution has hardwired some general 
affinities into canonical dimers, their existence is highly context specific and 
requires a full understanding of co-factors and post-translational modifications that 
may be contributing to the final outcome of any particular signaling event. 
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Chapter 4 Determining the Structural Basis of the 
p50:HDAC1 Interface 
 
4.1 Introduction 
Studies mentioned previously have suggested that p50 binds HDAC1 at 
least in the cell lines in which the original observation have been published. Since 
then, others have shown that the interaction between p50 and HDAC1 may in part 
be responsible for changes in gene transcription activity at certain NF-κB promotors 
[102]. However, this information has been observational and has lacked a deep 
structural understanding of how these proteins may be interacting as well as the 
mechanism for the formation of this complex in general. It has been originally 
reported by Zhong et. al. that phosphorylation plays a major role in whether or not 
p50:p65 heterodimers associate with the activating histone acetyl transferase p300 
or HDAC1 [103]. This study however did not determine how p50 was interacting 
with HDAC1 specifically and whether this held true in the context of p50 
homodimers on their own. In addition to work from Wilson et. al. which attributes 
much of the anti-inflammatory potential of p50 homodimer to its association with 
HDAC1 [58], Elsharkawy et. al. showed that HDAC1 activity was critical in the 
inhibition of pro-inflammatory genes by p50 [104]. While these reports all confirm 
the importance and presence of the complex, they do not elucidate its mechanism 
of formation or the precise nature of the interaction. 
Recently, Bandyopadhaya et. al. found that p50 may be playing a major role 
in tolerance (the ability of cells to subdue their reactions to repeated introduction to 
the same stimuli) and their study has shed more light on the nature of the 
interaction. They show that cells tolerized with bacterial quorum sensing molecule 
2-Aminoacetophenone leads to decreased HDAC1 mediated p65 acetylation and 
a reduction in p65:p300 binding. Moreover, this loss of p65 acetylation coincided 
with an increase in p50:HDAC1 binding and a decrease in p50:p65 binding [102]. 
These results confirm Zhong’s original findings and provides further evidence that 
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HDAC1, through interaction with p50, is a major repressor of NF-κB driven pro-
inflammatory gene expression. 
4.2 Aims 
Apart from these studies little has been done to more finely elucidate the 
structural interaction between p50 and HDAC1. As such this chapter aims to: 
• Determine the conditions under which p50 associates with HDAC1. 
 
• Determine the exact structural interaction between the p50 and HDAC1 
molecules. 
 
• Understand the effects and implications of the observed binding between the 
two proteins. 
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4.3 Results 
4.3.1 p50 associates with HDAC1 in resting cells 
 Evidence for a direct association between p50 and HDAC1 in the literature 
is sparse, as eluded to earlier [123]. As such the assertions commonly made in the 
literature that p50 is present in the nucleus of resting cells and associates with 
HDAC1 needed to be re-examined. As HDAC1 is a well-established nuclear 
specific protein, the nuclear activity of p50 in unstimulated cells needed to be 
determined. Immunofluorescence for endogenous p50 was performed in U2OS 
cells under normal culture conditions with a variety of primary antibodies raised 
against p50. Under all conditions tested, many antibodies produced high, 
undesirable levels of background and were not conclusive, however, 
representative images shown in Figure 4.1 do suggest both a nuclear and 
cytoplasmic pool of p50 when detected by SC 114-X (Santa Cruz) anti-p50/p105.  
Given these technical issues with immunofluorescence, it was decided to 
attempt to confirm an interaction between p50 and HDAC1 in whole cell lysates 
using immunoprecipitation (IP). As such, a protocol was developed to facilitate p50 
immunoprecipitation from cells and tissue using the commercially available 
antibody (Abcam ab7971), the details of which can be found in the relevant 
methods. After trying several conditions and systems, p50 was successfully 
immuno-precipitated from U2OS cells, shown in Figure 4.2A. To determine if p50 
interacts with HDAC1, however, further optimization was required to preserve 
protein-protein interactions within the IP. Using the same p50 antibody mentioned 
previously as well as negative controls including non-specific rabbit IgG and mouse 
anti Gal4 antibody, IP experiments were performed using an anti-p65 antibody 
(Santa Cruz, SC-37) to see if the canonical association of p50 with p65 could be 
detected in a co-IP assay. Under optimized conditions used in Figure 4.2B, p50 is 
found associated with IP’ed p65 validating the conditions used. Unfortunately, 
during the course of these experiments, the originally optimized antibody became 
unavailable from the manufacturer and therefore, three alternatives had to be 
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Confocal Immunofluorescent microscopy of U2OS cells with clear nuclear and 
cytoplasmic pools of wild type, endogenous p50 in resting cells. p50 shown in red 
(Rhodamine) with DNA shown in blue (DAPI) as well as a merged channel. 
 
 
 
 
 
Figure 4.1 Immunofluorescent Microscopy of Endogenous p50/p105 
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A. Immunoprecipitation of p50 from U2OS cells showing a reduction of p50 in IP 
supernatant following incubation with anti p50/p105 antibody (Abcam) and subsequent 
enrichment in IP samples. B. Western blot for p50 showing optimization of co-
immunoprecipitation assay in U2OS cells confirming co-precipitation of p50 along with 
p65.(Direct IP of p50 achieved using p50 antibody, IgG and Gal4 used as a negative 
controls and p65 to test co-ip of p50)  C. Western blot of a Co-immunoprecipitation assay 
in wild type murine embryonic fibroblasts (MEF’s) to determine which a commercially 
available antibodies were capable of precipitation of p50 for further experiments (IP 
antibodies used were IgG as a negative control, p50 D7H5M (CST), p50 H119 (Santa 
Cruz) and p50 114x (Santa Cruz) along with p65 to insure co-ip conditions were 
maintained .   
 
 
Figure 4.2 Optimization of p50 Immunoprecipitation Assays 
IP: Antibody 
IP Antibody 
IP: Antibody 
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screened under co-IP conditions to validate their effectiveness to IP p50. Shown in 
Figure 4.2C, two of the 4 antibodies tested successfully immuno-precipitated p50 
under co-IP conditions and these were used for the remainder of the study.   
Previous studies in cell lines have shown that p50 and p65 seem to associate 
with HDAC1 under resting conditions [103]. However, it was uncertain if this 
interaction could be observed in vivo. Therefore, wild type three-month-old whole 
liver was utilized from C57/B6 mice to perform endogenous co-IP assays for p50 
and HDAC1. Figure 4.3A shows that, at least by co-IP, p50 and p65 both do 
associate with HDAC1 in primary tissue. As these experiments were performed on 
healthy untreated wild type tissues, this experiment provides further evidence for 
the p50:HDAC1 association under resting conditions. If this is indeed the case then 
it was hypothesized that bound HDAC1 would dissociate or at least have reduced 
binding to p50 under conditions of NF-κB stimulation. To test this, HeLa cells were 
left untreated or treated with 10 ng/ml TNFɑ for six hours followed by co-IP assay 
for HDAC1 bound to p50. As shown in Figure 4.3B, in untreated cells, p50 co-
precipitated HDAC1 normally however upon TNFɑ stimulation this interaction 
appears to be severely attenuated. Together these experiments support the theory 
that p50, under resting conditions, recruits HDAC1 to the promotor of NF-κB target 
genes, however, it is unclear if other components exist in this complex. 
As stated previously, HDAC1 is a nuclear protein and is often found in 
nuclear remodeling complexes such NuRD and Sin3A complex [96,98]. To see if 
the p50:HDAC1 interaction was mediated by one of these repressor complexes, 
co-IP assays were performed for Sin3A and p50 under resting conditions. While 
strong interaction was observed between HDAC1 and Sin3A and between p50 and 
HDAC1 (Figure 4.4A), only a small association between p50 and Sin3A was 
observed (Figure 4.4B). This suggests that the p50:HDAC1 interaction is occurring 
independently of the Sin3A nuclear remodeling complex and that either another 
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A. Western blot of an endogenous co-immunoprecipitation assay performed with 
indicated antibodies in whole liver extracts of wild type untreated mice showing that 
HDAC1 is bound to p50 as well as p65 under resting conditions. B. Western blot analysis 
of an endogenous co-immunoprecipitation (co-IP) assay performed in HeLa cells which 
were unstimulated or treated with 10ng/ml TNFɑ. In unstimulated cells more HDAC1 is 
detected bound to p50 than in cells stimulated with TNFɑ. 
 
 
 
 
 
 
Figure 4.3 p50 Interacts with HDAC1 under Resting Conditions. 
IP: Antibody 
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A. Western blot analysis of a co-IP assay using antibodies against p50 or Sin3A verifying 
the presence of HDAC1 in complex with both p50 or Sin3A in U2OS cells. B. Western blot 
analysis of a co-IP assay to verify the pull down of p50 and Sin3A by their respective 
antibodies in U2OS cells. It should be noted that p50 signal is observed in the Sin3A IP. 
C. Western blot analysis of a Sin3A siRNA time course used to optimize a Sin3A 
knockdown in U2OS cells. Cells were incubated with siRNA for 12, 24 or 48 hours with 
partial knockdown observed at 24 hours compared to a scramble siRNA control. 
 
 
 
Figure 4.4 Investigation of Tertiary Members of the p50:HDAC1 Complex 
IP: Antibody 
IP: Antibody 
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complex, such as the NuRD complex, is mediating the interaction or p50 is forming 
direct contacts with HDAC1. Further studies using the partial Sin3A knockdown at 
24 hours in Figure 4.4C failed to generate meaningful changes in p50:HDAC1 
interaction by co-IP. Given this insecurity of whether p50 interacts with HDAC1 
directly or through an associated complex, it was decided to identify the structural 
basis for this interaction at a residue level to provide some evidence for a direct 
interaction. 
4.3.2 Predicting the p50:HDAC1 Interaction and Generation of 
Recombinant Proteins 
Given the available crystal structures of p50 and HDAC1 it was decided to 
see what information could be gained from in silico modelling of the two proteins. 
As such, the p50 homodimer crystal structure (PDB ID 1NFK) and the HDAC1 
crystal structure (PDB ID 4BKX) were supplied to the rigid body docking algorithm 
GRAMM-X. Using conformations of residues observed in the crystal structure 
without DNA crystalized with p50 (Figure 4.5A), surface residues of HDAC1 were 
matched for the lowest free energy conformation configuration against p50 
residues. This analysis returned a list of possible direct binding orientations 
assigned and ordered by a score determined primarily by free energy predictions. 
Of this list the top ten hits were visualized in the three-dimensional structure 
(Figure 4.5B). These top ten hits were further refined based on the symmetry of 
p50, near similar orientations as well as any obvious DNA clash (Figure 4.5C). 
This further refinement produced two potential sites of direct interaction that 
suggested HDAC1 would bind either in the cleft formed by the two globular 
domains of p50 or in the region of known interaction with other NF-κB interacting 
proteins previously established (IκBɑ, Importin ɑ and BCL3). This result suggested 
that HDAC1 may be binding p50 in a manner like that of other interacting proteins 
or at a novel site. With these two possible orientations in hand it was decided to 
test these possible interaction sites in vitro and attempt to co-crystalize the proteins 
to generate a bound crystal structure for the interaction. 
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A. Crystal structure surface of a p50 (orange, PDB ID 1NFK) homodimer with DNA 
removed used as the receptor and HDAC1 (yellow, PDB ID 4BKX) as the ligand.                  
B. Surface structure of p50 along with the highest scoring orientations of HDAC1 returned 
by the GRAMMX algorithm highlighting numerus possible binding orientations and 
contacts. C. Top two highest scoring HDAC1 binding orientations after replicates (caused 
by symmetry) and molecules which would clash with DNA were removed. 
Figure 4.5 Direct binding prediction of the p50:HDAC1 interaction by the GRAMMX 
Server for Protein-Protein -Interactions 
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To achieve protein crystallization the petM30 vector system was used which 
generates HIS-GST fusion proteins with a linker which can be cleaved by TEV 
protease. As such TEV protease was recombinantly overexpressed in E coli. 
following usual recombinant protein generation and extraction techniques. 
Expressed TEV protease was purified by affinity chromatography on a nickel 
column and collected in fractions as seen in Figure 4.6. The three highest fractions 
of this generated HIS-TEV was then stored at -80°C to be used to remove tags 
from future generated fusion proteins. Given the previously established data in the 
crystal structures of p50 and HDAC1 and their associated papers, conditions for 
the purification of p50 from E coli. have been published, however, source material 
for the HDAC1 crystal structure was derived from protein expressed in human cells 
[95,106]. Using these published conditions for p50 as a starting point, full length as 
well as previously crystalized fragment length versions of both p50 and HDAC1 
were cloned into petM30 vectors using Gibson assembly (Figure 4.7A shows PCR 
generated fragments before ligation into vector). As p50 is known to be expressed 
in bacterial systems, full length p50 was the first protein to be tested for expression 
in Rosetta 2 competent bacteria. Following lysis and nickel affinity purification, high 
percentile imidazole fractions were found to contain a full length p50-GST-HIS 
fusion protein at the expected molecular weight of near 77 kDa (Figure 4.7B). The 
top 4 fractions of this elution were pooled and further purified by GST affinity. This 
purified GST-p50 was then analyzed by serial dilution western blot to insure the 
purified fusion protein was p50. In Figure 4.7C serial dilution of pure p50 yielded a 
band detected by anti-p50 antibody at the same molecular weight observed by 
Coomassie blue stain. This verified pure p50 was then incubated with previously 
generated TEV protease followed by another round of HIS affinity purification with 
the flow though containing pure p50 which had its GST-HIS cleaved. This pure 
untagged form of p50 was then further purified by dialysis and stored at -80°C for 
future applications (Figure 4.7D).  
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Coomassie stain of an Imidazole elution gradient used to purify recombinant TEV 
protease expressed in Rosetta (II) DH5α E. coli to be used as a cleavage enzyme in the 
removal of purification tags from recombinant proteins. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Coomassie Blue Stain of Purified TEV Protease. 
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A. DNA electrophoresis PCR products including p50 and HDAC1 in full and indicated 
fragment lengths containing 5’ and 3’ regions complimentary to petM30 vector backbone. 
B. Coomassie stain showing an Imidazole gradient elution of full length p50-GST-His.       
C. Western blot analysis of a serial dilution of pure p50-GST-HIS to confirm its identity.   
D. Coomassie stain of pure full length recombinant p50 after GST-His cleavage and 
dialysis. Two lower molecular weight products are noted and assumed to be degradation 
products of p50. 
Figure 4.7 Generation of Expression Constructs of p50, p65 and HDAC1: 
Purification of recombinant p50 
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Having successfully purified recombinant p50, this same protocol was 
applied to HDAC1. Unfortunately, no appreciable amount of protein was observed. 
Therefore an expression assay was performed. Full and fragment length HDAC1 
along with fragment length wild type p65 were transformed into various expression 
strains of E coli. in three different types of culture media. After induction the whole 
cell lysate, soluble lysate fraction, GST purification flow through and GST 
purification eluate were analyzed by Coomassie Blue stain to determine if any 
protein was produced under any condition, and to determine its solubility. Seen in 
Figure 4.8A, full length HDAC1 was not observed under any condition of 
expression tested, however some expression of fragment length HDAC1 was 
observed in some cases (Figure 4.8B). Specifically, Arctic and Rossetta II cells in 
auto induction media seem to provide low levels of pure fragment HDAC1, 
however, the majority of this protein was observed in the whole lysate fraction. This 
suggested that HDAC1 could be produced in these cells but is highly insoluble. 
Subsequent attempts to increase solubility and yield of the protein were, however, 
unsuccessful. These same experiments were performed on the previously purified 
crystallographic length version of p65 as well and is shown in Figure 4.9. Pure p65 
was observed under a number of conditions, however, Arctic cells in auto induction 
media provided a high yield, soluble, low contamination pool of p65 with little to no 
observable degradation products. Originally performed as a control experiment, 
this also provided optimized conditions for the expression of pure p65. Given the 
inability to produce high quantities of stable HDAC1, however, another method of 
determining the interacting residues between p50 and HDAC1 was required. 
4.3.3 Peptide Arrays Identify the Nuclear Localization Signal of p50 as 
the Primary Motif of Interaction with HDAC1 
 With trials to produce recombinant HDAC1 unsuccessful, peptide array 
technology was used to identify residues critical for the p50:HDAC1 interaction. 
Peptide arrays consisting of 18 amino acid fragments of p50 shifted by three amino  
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A-B. Coomassie Blue stain of a recombinant expression assay performed in LB, TB or 
Auto Induction Media (AIM) to determine the viability of selected HDAC1 construct 
expression in five strains of E. Coli. Samples were fractionated by 8% SDS-PAGE. Arrows 
indicate expected molecular weights of target proteins. More detail in Figure 4.9. 
Figure 4.8 Recombinant Protein Expression Assay for Full and Fragment Length 
HDAC1 
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Coomassie Blue stain of a recombinant expression assay performed in LB, TB or Auto 
Induction Media (AIM) to determine the viability of a previously crystalized fragment of p65 
expression in five strains of E. Coli. Samples of whole cell lysate, clarified soluble lysate 
(by centrifugation), GST column flow through filtrate and GST column eluate were 
fractionated by 8% SDS-PAGE to determine if produced recombinant protein was being 
lost during purification. Highest yield of recombinant p65 was obtained in Artic express 
cells in AIM media after GST purification. 
 
 
 
 
Figure 4.9 Recombinant Protein Expression Assay of p65 
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acids covering the full length of human p50 and HDAC1 were kindly provided by 
the Kiely Lab (University of Limerick). Firstly, HDAC1 peptide arrays were probed 
with previously generated recombinant p50 and probed with anti-p50 antibody to 
determine if p50 formed stable interactions with any fragments of HDAC1. Upon 
development several specific peptides of HDAC1 were detected to facilitate this 
p50 interaction (Figure 4.10A and B). Positive peptides identified were then 
mapped to the crystal structure of HDAC1 to determine these locations in three 
dimensional space. It was determined that only one site of positivity was contained 
within the crystal structure of HDAC1, however, this site was on an external β-sheet 
and ɑ-helix of the globular catalytic core of HDAC1 suggesting it could be suitable 
as an interacting motif (Figure 4.10C). To examine this in more detail, this region 
was analyzed in relation to the earlier predicted possible binding orientations and 
it was found that the ɑ-Helix portion of the identified site would make direct contact 
with the c-terminal portion of the p50 rel homology domain at a site similar to p50 
interactions with IκB’s. This observation is visualized in Figure 4.11A and B which 
shows the possible binding orientation of p50 and HDAC1 as well as the sequence 
in HDAC1 positive for interaction on the peptide array. 
 In an attempt to confirm this observation, this entire experiment was 
repeated reciprocally. Recombinant human HDAC1 generated in insect cells and 
provided commercially was incubated with p50 peptide arrays (Figure 4.12 A and 
B) to determine if HDAC1 would have a specific affinity p50 peptides. Figure 4.12C 
highlights multiple possible points of interaction of HDAC1 along the p50 sequence. 
These peptides were then examined in the context of the full p50 crystal structure 
and it was observed that they all exist within the p50 crystal structure with the 
exception of the far C-terminal end of the more C-terminal positive peptide. Mapped 
onto the p50 crystal structure these four regions were highlighted and it was 
observed that while 3 new distinct regions were identified, one of the observed 
binding peptides lay at the previously identified region of possible interaction as 
predicted by in silico analysis as well as  
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A. HDAC1 peptide array in which 18 amino acid fragments of wild type HDAC1 hybridized 
to nitrocellulose probed with generated recombinant wild type p50 followed by anti p50-
HRP antibody. B. HDAC1 peptide array probed with anti p50-HRP antibody alone.              
C. Crystal structure of HDAC1 highlighting residues positive for p50 interaction (red) in 
relation to the catalytic core. 
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Figure 4.10 Mapping the p50 Interaction on HDAC1 
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A. Crystal structure of HDAC1 (yellow) and p50 (orange) in one of the GRAMMX predicted 
orientations proposed for binding with residues positive in the HDAC1 peptide array 
highlighted (red). B. The location of the peptide array predicted binding motif within the 
context of the full HDAC1 protein sequence. 
 
 
 
Figure 4.11 Comparison of Predicted p50-HDAC1 Binding and Peptide Array Data 
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A. p50 peptide array under UV light showing the location of all 120 peptides spanning the 
length of p50. B p50 peptide array probed with anti-HIS-HRP antibody to confirm the 
absence of non-specific binding. C. Peptide array of 120 sequential peptides of 18 amino 
acids spanning the length of p50 probed with recombinant HDAC1-Hisx3 highlighting 
multiple sights of potential interaction. D. All regions of potential interaction discovered in 
the peptide array mapped to the crystal structure of the p50 homodimer. 
 
 
 
Figure 4.12 Mapping the HDAC1 interaction on p50 
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the previous peptide array (Figure 4.12D). Together this evidence strongly 
suggests that p50 interacts with HDAC1 at some portion of the c-terminal region. 
Therefore, interaction with p50 in the region including the last 7 peptides in the p50 
array were further investigated. Sequential alanine substitution was performed on 
peptides in which each residue had been mutated to an alanine residue to 
determine the specific contribution of each residue to the interaction as well as 
identify the exact residues critical in the interaction. Upon re-probing with 
recombinant HDAC1, several changes in binding to p50 peptides were observed. 
Namely, variation in the binding of HDAC1 to p50 peptides occurred universally but 
the most dramatic changes were observed in peptide 120 where changes to the 
VQRKRQK motif resulted in ablation of the interaction (Figure 4.13A and B). This 
motif, it was observed, was not a part of the crystal structure of p50 however, the 
residues which showed the greatest change in interaction occurred in the region of 
p50 previously identified as the nuclear localization signal or NLS (Figure 4.13C). 
Furthermore, it was noted that while two of these residues are conserved in p65, 
all other nearby residues are unique to p50 (Figure 4.13D). Together this strongly 
suggests that p50 is bound by HDAC1 at its NLS in a manner similar to that of IκBɑ 
and may be masking its NLS for the duration of its interaction [124].  
4.3.4 Mutation of the p50 NLS Ablates its Interaction with HDAC1  
 To confirm this site as the key site of interaction between p50 and HDAC1 a 
number of mutations were carried out on NLS of p50. pcDNA3.1 mutant p50-Flag 
constructs were generated by site directed mutagenesis (Figure 4.14A). One of 
these mutants carried the full disruption of the NLS found in the peptide array. 
These mutant-expressing mammalian constructs were then transfected into Cos7 
cells along with their wild type HDAC1-HA fusion expressing pcDNA3.1 constructs 
and flag immuno-precipitated to determine their ability to bind HDAC1. Figure 
4.14B shows that HDAC1 is co-precipitated with wild type p50 as well as all mutant 
constructs with the exception of the total NLS ablation mutant. Interestingly partial  
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A. Alanine substitution peptide array of the terminal seven 18aa peptides probed with 
recombinant HDAC1 displaying differential binding based on specific amino acid changes. 
B. Representation of specific amino acids mutated to alanine and responsible for the 
apparent loss of interaction. Graph below indicates relative signal of each peptide as 
measured by densitometry C. Residues which attenuate the interaction between HDAC1 
and p50 peptides in context of the full-length protein beginning with V360 to L366. D. 
Consensus sequence alignment of p50 and p65 showing distinct residue differences in 
the region proposed to mediate the p50:HDAC1 interaction. 
 
Figure 4.13 Refinement of Residues Responsible for the p50:HDAC1 Interaction 
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A. DNA gel electrophoresis of four p50 constructs in which increasing mutations were 
made in the nuclear localization sequence (NLS) of p50 in accordance with peptide array 
data (left). Table of sequence changes made by site directed mutagenesis to the original 
wild type p50-FLAG construct (right). B. Western blot analysis of a FLAG 
immunoprecipitation assay of indicated mutant p50 expressed in Cos7 cells transiently 
transfected along with HDAC1-HA. Complete mutation of the indicated residues 
(Sequence 4 – p50Mu) result in a near total ablation of the p50:HDAC1 interaction in full 
length transiently transfected proteins. C. Western blot analysis of a FLAG Co-IP assay 
showing no difference of HDAC1 binding between WT or p50K365A in Cos-7 cells. D. 
Western blot analysis of an endogenous IP assay with an antibody specific to the nuclear 
Figure 4.14 Mutation of Key Residues in the NLS of p50 Ablates the p50:HDAC1 
Interaction. 
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localization sequence of p50 showing a loss of p50 pull down in p50Mu confirming the 
presence of a mutation in this region. 
 
mutants seemed to enhance p50’s affinity for HDAC1 however when the terminal 
lysine residue of the VQRKRQK motif is mutated to alanine the interaction is lost 
suggesting a crucial role for this lysine in the interaction. Nevertheless, when this 
amino acid is mutated on its own, and expressed in HeLa cells, there is no 
observable difference in binding of HDAC1 compared to wild type p50 (Figure 
4.14C). In addition to this observation it was also confirmed at the protein level that 
the fully disruptive mutant, here referred to as p50Mu did indeed contain a mutated 
motif by immunoprecipitation. HeLa cells transfected with wild type or p50Mu were 
immuno-precipitated using an NLS specific anti-p50 antibody. In the western blot 
analysis of this experiment it can be shown that wild type but not p50Mu can be 
precipitated using the NLS specific antibody confirming protein residue changes in 
this region (Figure 4.14D). 
 As the only evidence for this loss of interaction thus far was in a system 
where HDAC1 was overexpressed, FLAG constructs of wild type and p50Mu were 
transfected into HeLa cells to determine if mutant p50 would interact with 
endogenous HDAC1. Positive interaction with wild type but not p50Mu with HDAC1 
confirmed that this mutant attenuates p50’s ability to interact with endogenous 
HDAC1 in cells (Figure 4.15A). Moreover, this experiment was also performed in 
nfkb1-/- murine embryonic fibroblasts (MEF) to ensure the interaction was not 
occurring in wild type controls via interaction with endogenous p50. Therefore 
MEFs were similarly transfected and similar results obtained where wild type but 
not p50Mu is capable of co-precipitating endogenous HDAC1. Having generated a 
mutant capable of ablating the HDAC1 interaction, it was prudent to determine the 
effect this was having on the entire interactome of p50. As such, U2OS cells were 
transfected with wild type and p50Mu and flag IP’s performed to co-precipitate p50 
and all of its possible binding partners. Samples were then verified by silver stain 
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after separation by SDS-PAGE (Figure 4.15B) and then analyzed by mass 
spectrometry by the core Mass Spectrometry Facility at Newcastle University. 
Unfortunately, protein digestion and subsequent analysis did not yield viable data 
for either the wild type or p50Mu sample. Sample was provided on three separate 
occasions however peptides with weights corresponding to p50 residues were not 
identified in each case even though the presence of precipitated protein could be 
detected by western blot. Given the data presented previously, however, this region 
of p50 identified by peptide array and verified by multiple co-immunoprecipitation 
experiments suggest it is the site of interaction between p50 and HDAC1. 
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A. Western blot analysis of a FLAG co-immunoprecipitation assay of HeLa cells 
transiently transfected with WT or p50Mu confirming loss of interaction with endogenous 
HDAC1 under resting conditions. B. Western blot analysis of a FLAG Co-IP assay of 
nfkb1-/- MEFs showing a loss of interaction with endogenous HDAC1 in p50Mu compared 
to WT. C. Silver stain of WT or p50Mu FLAG IP showing a loss of co-precipitated targets 
near 60kDa in p50Mu compared to WT. 
 
 
 
 
Figure 4.15 p50Mu disrupts endogenous p50:HDAC1 Interaction in Multiple Cell 
Types. 
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4.4 Discussion 
p50/p105 performs numerous complex roles in cells in both its precursor, 
p105, and p50 forms. In both forms it participates in numerous protein-protein 
interactions in both the cytoplasm and nucleus of resting and stimulated cells. 
While as an IκB p105 is known to interact with other NF-κB subunits and in other 
pathways such as Tpl2 [125], p50’s interactions, some of which are known, are 
rarely investigated with structural detail. Recently, one such interaction has been 
investigated at this level of detail and provides insights into the mechanisms of how 
p50 carries out its complex role in cells. Bcl3 has been shown previously to bind 
p50, however Collins et. al. showed that this interaction was at a region in the p50 
nuclear localization sequence and share residues that have been previously shown 
at the site of interaction between p50 and IκB’s as well as Importins [73]. Given this 
information and the uncertainty of whether or not the p50:HDAC1 interaction was 
direct or mediated by a third party, this investigation into the potential p50:HDAC1 
interface was approached in a blinded fashion.  
4.4.1 Nuclear p50 interacts with HDAC1 in resting cells in a Sin3A 
independent manner 
Having confirmed the p50:HDAC1 in vivo and in vitro in resting cells 
particularly, a meaningful question remains regarding other members of this 
complex. Canonically, HDAC1 is considered an essential component of cellular 
machinery responsible for general shifts in chromatin organization in all cell types 
[93]. In this role however, it is most often associated as the catalytic core of 
complexes such as the NuRD and Sin3A complex and not as a free agent in the 
nucleus. Data presented in this chapter in the form of in silico predictions and 
peptide arrays do suggest that free HDAC1 could bind p50 with reasonable affinity 
and in a fashion allosteric to its active site. Moreover, co-IP assays suggest that 
one of the more well-known HDAC1 complex partners, Sin3A, cannot readily be 
observed interacting with p50 (Figure 4.4). Given that according to peptide array 
and prediction data, the p50:HDAC1 interaction occurs on an external alpha helix 
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of HDAC1 on the opposite side of the molecule to the catalytic core of the molecule, 
p50 could be interacting directly with a free form of HDAC1 and from the basis of 
a yet understood nuclear remodeling complex. Another important consideration 
given that the interface on p50 which is implicated as the HDAC1 binding motif is 
also its nuclear localization signal is that this loss of interaction is not simply due to 
the proteins existing in different cellular compartments. This specific point is 
address in chapter five but is an important possible interpretation of observed 
results.  
4.4.2 Loss of p50’s NLS Leads to a loss of HDAC1 Interaction 
The VQKRKQK motif which forms a part of the p50 NLS identified as critical 
to the HDAC1 interaction contains interesting properties. During the course of 
performing sequential mutation it was observed that loss of some of these residues 
provided an increase in the p50:HDAC1 interaction by IP while total loss was only 
achieved after mutation of all K and R residues. Indeed, single mutation of the 
terminal lysine residue on its own did not seem to have an impact on the interaction 
when compared to wild type. Given the high concentration of residues which may 
be acetylated however, one could argue that p50 is a target of HDAC1 and not a 
complex partner. While these sites have never been reported as acetylated 
residues, one could argue that acetylation at a protein inhibitor site may be serving 
a different function. A potential weakness of this study would then be that this 
possibility was not ruled out experimentally, however this interaction not governed 
a single amino acid. Additionally, it is unclear if even several continuous 
deacetylation events at this location would prove enough to retain an HDAC1 signal 
by co-IP in all of the conditions in which it has been observed. Therefore, using 
data presented in this chapter one can argue that p50 is recruiting HDAC1 via its 
nuclear localization signal by direct interaction and independent of other canonical 
HDAC1 complexes. Moreover, this recruitment, as determined by residue contacts 
and molecule orientation, is serving to poise HDAC1 as an effector molecule on 
surrounding proteins such as nearby histones to ensure gene regions bound by 
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p50 homodimers remain switched off. The molecular orientation indicated by both 
predictive software and in vitro experiments suggest that contacts made between 
p50 and HDAC1 leave the catalytic core of HDAC1 accessible to nearby proteins. 
It is conceivable then, that any proteins in the vicinity that can be deacetylated 
allowing p50 homodimers to locally target genes for three dimensional 
rearrangement based on their occupancy on DNA sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
Chapter 5 Function of p50Mu Mutant in the Context of a Loss of 
HDAC1 Interaction 
 
5.1 Introduction 
The dogma related to NF-κB activation and signaling pathways converge on 
the principle that dimers are sequestered in the cytoplasm of resting cells by the 
IκB’s. While others argue a more dynamic system rather than this binary inhibited 
or active state, it is clear that nuclear localization is the key step for the induction 
of gene transcription by any transcription factor. As such, the nuclear localization 
signal of transcription factors plays a major role in gene activation. Data in chapter 
4 strongly suggested that p50’s nuclear localization sequence serves as the region 
of interaction between it and HDAC1. Also, it is known from the wider literature that 
this region is also important for the binding of BCL3, Importin ɑ, IκBɑ as well as the 
ankyrin repeats of p105 during self-inhibition [112]. These studies all suggest that 
this region of p50 may be acting as a dynamic scaffold for both the cytoplasmic 
and nuclear control of p50 function. However, more important to understanding the 
p50:HDAC1 interaction is to determine HDAC1’s specific contribution to p50’s 
inhibitory action.  
Previous published work has shown that p50 is a potent deactivator of 
immune cell regulatory and inflammatory genes [38]. In particular, it has been 
shown that, in addition to canonical pro-inflammatory genes such as IL6, p50 
represses genes related closely to the activation of and recruitment of immune cells 
including genes of the CXCL(cxc motif ligand) and MMP (Matrix metalloprotease) 
families among others [58]. However, the extent to which this repression relies on 
the interaction with HDAC1 is not well understood. While Elsarkawy et al. showed 
that MMP13 repression by p50 seemed to be HDAC1 dependent, little has been 
done to interrogate whether the interaction with HDAC1 provides most if not all of 
the repressive potential of p50 homodimers [104]. Having generated a tool in vitro 
that seems to interrupt this p50 HDAC1 interaction (p50Mu) but lacks the expression 
challenges of other mutants such as the p50S343A previously described, a number 
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of elusive question regarding the role of HDAC1 in p50 directed NF-κB gene 
repression can be interrogated. 
 
5.2 Aims 
Having identified the major region of interaction between p50 and HDAC1 and 
generated a construct of p50 that disrupts this interaction, the aims of this chapter 
are as follows: 
• To determine the effect of the p50Mu mutation on canonical function of p50 
including nuclear localization and binding of IκBα and p65. 
• To determine the contribution of HDAC1 to p50 dependent NF-κB gene 
repression. 
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5.3 Results 
5.3.1 Mutation of p50 which causes a loss of HDAC1 Interaction Has 
no Effect on Canonical p50 Interactions 
 As shown previously, p50Mu is unable to bind HDAC1 in a co-IP assay 
(Figure 4.15). Given this result it was important to determine if this loss of HDAC1 
provided any functional changes in cells or within the NF-κB signaling pathway. To 
determine this, multiple cell lines were tested for NF-κB and HDAC1 protein 
expression. Profiled cell types are shown in Figure 5.1. Subsequent to this analysis 
U2OS cells (cells which displayed proportionate abundant expression of all 
components) and nfkb1-/- MEF’s (used to determine the mutant’s effects 
specifically) were selected for further experiments. Arguably, one of the most well 
defined roles of p50 is that of a p50:p65 heterodimer so it was important to 
determine if this interaction remained intact. Shown in Figure 5.2A and B, U2OS 
and COS7 cells respectively when transfected with either WT or p50Mu showed 
similar levels of p65 interaction as determined by flag co-IP assay. While this 
confirmed canonical dimer assembly, it is also important to remember that the 
major factor determining NF-κB activity is the ability of the subunits to be inhibited 
in the cytoplasm by the IκB’s. As such, canonical inhibitor of p65:p50 action, IκBɑ, 
was used in a co-IP assay to determine if reconstituted nfkb1-/- MEFs formed 
traditional p65:p50:IκBɑ complexes. Seen in Figure 5.2C, when immuno-
precipitation is performed using an antibody against IκBɑ, both p65 and 
reconstituted wild type and p50Mu are observed at similar levels. This evidence 
suggests that not only is canonical p50:p65 dimer unaffected by the p50 mutation 
but neither is the ability of IκBɑ to bind p50, providing strong evidence that the NF-
κB pathway is unaffected at this stage. 
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Western blot analysis of multiple cell types for expression of NF-κB components and 
HDAC1 to determine a suitable system to utilize to interrogate the effect of the p50:HDAC1 
complex. LX-2, THP1 and U2OS lines are of human origin compared to murine embryonic 
fibroblasts and explains the observed differences in molecular weight as proteins are 
different sizes between species. 
 
 
 
 
 
 
 
 
 
Figure 5.1 Analysis of various cell types for expression of key complex 
components. 
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A. Western blot analysis of a flag co-IP assay in U2OS cells transfected with p50Mu or wild 
type p50 confirming no difference in p65 pull down. B. Western blot analysis of a flag co-
IP assay in Cos7 cells transfected with p50Mu or wild type p50 confirming no difference in 
p65 pull down. C. Western blot analysis of a flag co-IP assay in nfkb1-/- MEFs transfected 
with p50Mu or wild type p50 showing integrity of the p50:p65:IκBα complex. 
 
 
 
 
 
 
 
Figure 5.2 p50Mu does not affect its ability to interact with p65 or IκBα 
U2OS 
COS7 
MEFs 
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5.3.2 Mutation of p50 which causes a loss of HDAC1 Interaction Does 
not Inhibit Nuclear Localization 
Another major component of NF-κB signaling is the ability of subunits to, 
once released from inhibitors, translocate to the nucleus to carry out their 
transcription-related activity. Since the mutation needed to block p50:HDAC1 
interaction occurs predominantly within the nuclear localization sequence of p50, it 
was prudent to determine if this mutation was having an effect on p50’s ability to 
enter the nucleus. Therefore nfkb1-/- MEFs (Figure 5.3A) and U2OS cells (Figure 
5.3B) were transfected with either wild type or p50Mu and nuclear and cytoplasmic 
extracts generated to determine the approximate proportions of p50 in each cellular 
compartment. As can been seen in the relevant figures mentioned above, in both 
cases, wild type and p50Mu are present in both the nuclear and cytoplasmic 
compartments of the cells examined. Additionally, there appears to be no 
difference between wild type p50 and p50Mu in terms of the ratio of proteins in each 
compartment which suggests that the proteins are behaving similarly and the 
mutation is not having an effect on nuclear localization. 
Since this finding disagrees with previously reported data suggesting an 
absolute requirement for p50’s nuclear localization sequence for nuclear import, it 
was decided to show this nuclear localization by a different method. Therefore, 
U2OS cells were transfected with ether wild type or p50Mu and probed by confocal 
immunofluorescence to determine the location of transfected p50 within the cell. 
Seen in Figure 5.3C, a clear nuclear pool of p50 is observed in both wild type and 
p50Mu transfected cells. However, a cytoplasmic pool is only observed in p50Mu. 
This may be a cause for some concern but may be explained by the difference in 
epitope availability due to the proximity of the mutation to the FLAG tag used in this 
assay or that the efficiency of nuclear import/shuttling may be slightly impaired in 
p50Mu. Nevertheless, these experiments show that a mutation of this magnitude in 
the NLS of p50 does not affect its ability to enter the nucleus. 
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A. Western blot of nuclear and cytoplasmic extracts from transiently transfected nfkb1-/- 
MEFs showing p50 nuclear translocation is unaffected by the mutation required to disrupt 
HDAC1 interaction despite its proximity to and inclusion of a portion of the nuclear 
localization sequence. B. Western blot of nuclear and cytoplasmic extracts from 
transiently transfected U2OS cells also showing p50 nuclear translocation is unaffected 
by the p50Mu mutation. C. Immunofluorescence confocal microscopy of U2OS cells 
transiently transfected with WT-FLAG or p50HI-FLAG detected by anti-FLAG-FITC 
confirming nuclear localization by both proteins. Scale Bar =50μm. 
 
Figure 5.3 p50Mu does not affect nuclear localization. 
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5.3.3 p50Mu Does not alter DNA binding but increases κB Promoter 
Acetylation 
 Given that the mutation in p50 established to disrupt the p50:HDAC1 
interaction did not cause a significant interruption of canonical dimerization, 
inhibition and nuclear localization, we next wanted to confirm it maintained its ability 
to bind DNA and subsequently upregulate κB driven genes. Therefore nfkb1-/- 
MEF’s were transfected with either wild type or p50Mu and one of three luciferase 
reporter constructs which contained 3x synthetic κB site promoter or the 
endogenously occurring IκBɑ or IL-6 promotors. The ability of either wild type or 
p50Mu to bind these sites was then determined by relative luminesce readout. In 
each case, as seen in Figure 5.4, there was no significant difference in relative 
luminescence observed in any of the three reporters used. While these results have 
to be interpreted in the context of a p50 reconstitution including reconstitution of 
the p50:p65 heterodimer, this strongly suggests that p50Mu does not affect p50’s 
ability to bind DNA and promote gene transcription.  
 To gather more evidence in support of this, nfkb1-/- MEF’s were again 
transfected with wild type or p50Mu and a ChIP assay was performed using the 
FLAG epitope on the transfected proteins. Figure 5.5 shows that p50Mu and wild 
type p50 both bind known p50 target genes. While there appears to be a slight non-
significant reduction in the case of p50Mu, this evidence further supports p50Mu’s 
ability to both enter the nucleus of cells and directly bind and drive known target 
genes. Given these findings, it was then important to determine if this p50 present 
at known κB promotors was having an effect of the overall acetylation of histones 
nearby. To test this another ChIP assay was performed using an antibody against 
pan Histone H3 acetylation in nfkb1-/- MEF’s that had been reconstituted with wild 
type or p50Mu for 48 hours. Highlighted in Figure 5.6, previously described p50 
target genes cxcl1 and cxcl2 display increased acetylation when cells are 
reconstituted with p50Mu and this increase rose to significance in the case of the 
cxcl2 promotor. Together these experiments suggest that p50Mu, due to its inability  
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Luciferase reporter assay for a triple NF-κB promoter and IκBα promoter and IL-6 
promotor in MEFs  reconstituted with WT or p50Mu confirming similar ability to promote 
NF-κB dependent gene transcription. 
 
 
 
 
Figure 5.4 p50Mu does not alter DNA binding 
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ChIP assay for p50 in nfkb1-/- MEFs confirming similar binding at cxcl1 and cxcl2 
promotors in cells reconstituted with wild type or p50Mu. 
 
 
 
 
 
 
 
Figure 5.5 p50Mu does not affect p50's ability to bind known target promoters 
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Pan acetyl Histone 3 ChIP  assay qRT-PCR on nfkb1-/- MEFs demonstrating a significant 
increase in acetylation of the well-known p50 target gene cxcl2 when cells are transfected 
with a version of p50 unable to bind HDAC1 (p50Mu) compared to WT (t-test p=0.021). 
The same trend is observed in the target gene cxcl1. 
 
 
 
 
 
 
 
 
Figure 5.6 Cells reconstituted with p50Mu possess significantly more acetylation 
at promoters of known p50 target genes. 
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to recruit HDAC1, leads to increased κB promotor H3 acetylation and the loss of 
basil gene repression provided in resting cells by p50 homodimers. 
5.3.4 p50Mu recapitulates the pro-inflammatory phenotype observed 
when p50 homodimers are lost 
Given this evidence that p50Mu’s ability to carry out canonical NF-κB activities 
appears unimpaired, yet acetylation of κB driven target genes in cell with p50Mu is 
increased, we hypothesize that this increase in acetylation would be reflected as 
an increase in pro-inflammatory gene expression in both resting and stimulated 
cells which have been reconstituted with p50Mu. To test this, the response of nfkb1-
/- MEFs to canonical NF-κB activator TNFɑ at one, three and six hours was 
observed by RT-qPCR for known pro-inflammatory genes IL-6 and cxcl10. Seen in 
Figure 5.7, significant (p=0.042) upregulation of both IL-6 and cxcl10 was 
observed after one hour of stimulation. This increased to highly significant 
(p=0.0012) after six hours. As such the six-hour time point was chosen for further 
experiments to both insure capture of late phase genes in the analysis as well as 
accurately detect any subtle changes in transcripts. 
Using this six-hour stimulation regime, nfkb1-/- MEFs were equally 
transfected (Figure 5.8A) with either wild type or p50Mu for 24 hours and then left 
untreated or treated with TNFɑ. Relative gene expression under these conditions 
is shown in Figure 5.8B. In each case, the known p50 target genes showed a 
significant upregulation of gene expression in cells reconstituted with p50Mu 
compared to wild type upon TNFɑ stimulation. Moreover, this upregulation was also 
observed in unstimulated cells in the case of IL-6. This data suggests that p50Mu, 
due to its inability to recruit HDAC1, is enhancing gene expression of this subset 
of pro inflammatory genes. To confirm that this increase in transcript was reflective 
of a meaningful change in protein expression, an ELISA for IL-6 was performed on 
supernatant taken from these treated cells. Shown in Figure 5.9, a significant 
increase in secreted IL-6 was also observed in cell reconstituted with p50Mu and 
stimulated with TNFɑ compared to wild type p50. 
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RT-qPCR of two well-known p50 inflammatory target genes cxcl10 and IL-6 untreated or 
treated with 10ng/ml TNFα at various time points to determine optimal response times for 
functional characterization. Significant increase in gene transcription is observed at all 
time points between treated and untreated cells with greatest difference observed at six 
hours (p=0.042 at 1 hour and p=0.0012 at 6 hours as determined by unpaired students t-
test). 
 
 
 
Figure 5.7 TNFα time course in nfkb1-/- cells 
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A. Western blot analysis confirming equal transient transfection of WT and p50Mu in    
nfkb1-/- MEFs untreated or treated with TNFα. B. RT-qPCR demonstrating a significant 
increase in mRNA expression of well-known p50 repressed genes in the absence of 
HDAC1 interaction (p50Mu). IL-6 p=0.002, cxcl2 p=0.0002, cxcl1 p=0.004, cxcl10 p= 0.048 
and Mmmp13 p=0.0004. P values generated by t-test. 
 
 
Figure 5.8 Cells reconstituted with p50Mu display a more pro-inflammatory 
phenotype in comparison to wild type. 
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ELISA analysis of cell media showing a significant increase in released IL-6 in cells 
stimulated with TNFα (p= 0.047) from cells reconstituted with p50Mu compared to wild 
type. 
 
 
 
 
 
 
 
Figure 5.9 Cells reconstituted with p50Mu secrete more IL-6 than wild type. 
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Finally, to more directly compare the effects of p50Mu to that of the known 
loss of p50 homodimer phenotypes nfkb1-/- MEF’s were reconstituted with wild type 
or p50Mu for 24 hours and then either left untreated or treated with TNFɑ for six 
hours. Following this, media was harvested and used to perform a neutrophil 
chemotaxis assay to determine if cells lacking the p50:HDAC1 interaction provided 
stronger neutrophil recruitment potential (Figure 5.10A). Migrated neutrophil 
counts show that cells reconstituted with p50Mu attracted significantly more 
neutrophils than wild type p50 when stimulated with TNFɑ (Figure 5.10B). These 
results, corroborated by representative images (Figure 5.10C) and western blot 
transfection controls (Figure 5.10D), suggest that in the absence of the ability to 
bind HDAC1 p50 loses its innate repressive effect on pro-inflammatory target 
genes. Taken together with previous findings, a mechanism by which p50 
homodimers recruit HDAC1 to κB sites and silence gene expression there through 
histone deacetylation is further implicated. 
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A. Schematic of a neutrophil chemotaxis experiment highlighting timeframes. B. Cell 
counts post chemotaxis of murine neutrophils showing increased chemotaxis toward 
p50Mu conditioned media and significantly more infiltration when MEFs are stimulated with 
TNFα post transfection (p = 0.046). C. Representative images of neutrophils post 
chemotaxis in TNFα treated media. D. Western blot showing comparable transfection of 
WT and p50Mu from cells whose supernatant was used in the neutrophil chemotaxis 
experiment in both the presence and absence of TNFα. 
 
Figure 5.10 p50Mu promotes significantly more neutrophil chemotaxis 
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5.4 Discussion  
Evidence presented in this chapter strongly implicates HDAC1 as the key 
effector in p50 driven gene suppression. Additionally, it calls into question the 
previously reported absolute requirement for the NLS of p50 for nuclear import. 
These findings advance our understanding of NF-κB inhibition and provide a 
mechanism by which pro-inflammatory signaling events can be resolved. Data 
presented here are however not without limitations. 
5.4.1 p50 Nuclear localization sequence is not essential for nuclear 
transport. 
Given that p50Mu is a drastic ablation of the NLS, expectations were that 
there would be a severe impact on p50 nuclear import. However, no such loss of 
nuclear import has been observed as wells as no apparent effects on the formation 
of canonical complexes such as the p50:p65:IκBα complex. While these data 
strongly suggest these conclusions, in general precautions should be made when 
interpreting these results. For example, while the p50:p65:IκBα complex appears 
to be undisturbed, it is hard to rule out the possibility that p50Mu is having an impact 
on IκBα binding in particular. Due to the nature of this complex loss of p50 
interacting residues may not be enough on its own to block this interaction and the 
wild type p65 present is sufficient to keep the complex intact. Similarly, the finding 
that p50 nuclear localization is unimpaired may be due to the presence of p65 
aiding in nuclear import with its own intact NLS. Careful observations such as these 
have been the crux of the difficulty in teasing apart individual dimer and specific 
dimer pair functions. Therefore, experiments of this nature will have to always be 
interpreted in the context that observations are an average of all possible 
interactions including those with other members of the NF-κB family such as c-Rel. 
5.4.2 Interaction with HDAC1 is vital to p50’s ability to repress NF-κB target 
genes. 
Previous findings suggest that HDAC1 was required in a certain subset of 
genes for p50 dependent gene repression. However, data presented here further 
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corroborate this finding. The original p50 knock out phenotype as observed in 
nfkb1-/- is described as a systemic pro-inflammatory condition where systemic 
levels of chemokines such as IL-6 are elevated [126]. In this chapter, it is seen that 
cells reconstituted with p50 which is unable to recruit HDAC1 displays a similar 
phenotype. In addition, it has been shown that neutrophil infiltration is elevated in 
p50 knock out mice when subject to the carcinogen diethyl nitrosamine [58]. This 
is again phenocopied in vitro where neutrophils are more strongly attracted to 
supernatant from cells with an impaired p50:HDAC1 complex. These findings 
strongly suggest HDAC1 as the vital activator of p50 dependent gene repression, 
however this must be viewed in the context of the wider literature. It is known for 
example that p50 also binds nuclear Bcl3 which is proposed to protect it from 
proteasome mediated degradation [127]. Additionally, it has been shown that p50 
may recruit p300, a histone acetyl transferase, to directly upregulate gene 
transcription at the promoter of anti-inflammatory genes such as IL-10 [38]. While 
these interactions will be context specific and it is not clear how these interactions 
may co-exist, a potential hypothesis exists. In resting cells p50 homodimers may 
enter the nucleus and bind κB sites. This would offer the first line of repression as 
any induced active p50:p65 heterodimers would first have to displace these p50 
homodimers. Next, in a context dependent manner, potentially driven by post-
translational modifications such as phosphorylation, p50 may associate with 
HDAC1 or p300 to repress pro-inflammatory gene transcription or enhance anti-
inflammatory genes. Once nearby chromatin states have been appropriately 
modified, HDAC1 may share residency with Bcl3 of p50 homodimers ensuring 
chromatin remains in a repressed state and p50 homodimers remains in place and 
protected from premature removal and degradation. This is corroborated by the 
findings that BCL3 binds p50 via the same NLS region discovered to be critical in 
the HDAC1 interaction [73]. This model  summarized in Figure 5.11, best fits with 
observed experimental data here as well as the published literature whereby p50 
is orchestrating the repression of genes to ensure that potent activator signals do 
not induce unstainable levels of pro-inflammatory signals. This mechanism may 
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also be vital in the resolution of inflammation. As more IκB is transcribed and free 
p65 heterodimers are sequestered once more, the balance of dimers may shift to 
that of p50 homodimers which would then be free to orchestrate the epigenetic 
changed previously described. While this hypothesis does satisfy previous data 
more empirical evidence of this order of events is required for firmer claims to be 
made. What is certain now, however, is that HDAC1 is capable of significant 
changes to the epigenetic landscape of genes when recruited by p50. 
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Figure 5.11 Summary of a proposed mechanism for p50 homodimer and 
BCL3/HDAC1 mediated NF-κB transcription repression. 
In resting cells active subunit dimers are sequestered and bound to IκB’s in the cytoplasm 
while repressive p50 homodimers bind κB sites on DNA in the nucleus and through the 
recruitment of HDAC1 facilitates the deacetylation of histone tails and transcriptional 
repression. As the HDAC1 and BCL3 sites of interaction on p50 are shared, BCL3 would 
need to displace HDAC1 from homodimers and maintain their stability through 
ubiquitination blockade. Once activated by IκB degradation, p50:p65 heterodimers can be 
transported to the nucleus and displace p50 homodimers and through the recruitment of 
histone acetyl transferases initiate transcription from the required loci. 
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Chapter 6 General Discussion and Conclusion 
 
Data presented in this thesis has added to the growing body of published 
literature implicating p50 and HDAC1 as critical components of the pro-
inflammatory repression machinery in cells. In doing this it has also brought to light 
some of the complexities involved in studying multifaceted transcription factor 
families such as the NF-κB family. Teasing apart the intricacies of multiple subunits 
and the attribution to any observed effects promoted by those subunits must be 
done with great care. 
6.1 The complexities of NF-κB dimerization: control of the p50 
homodimer 
Discussed in chapter 3, dimer selection remains a poorly characterized area 
in part due to the complexities described earlier. Not only is it important to 
understand the context of the system being observed but also, as in the case of 
the S343A mutation, other unrelated factors that may not be obvious. As more 
evidence is gathered, it has become apparent that dimerization of subunits in 
particular is more complicated that previously envisioned. Innate sequence 
differences, availability of third party interactors as well as environments conducive 
to certain post-translational modifications along with cell and tissue specific 
differences most likely all conspire in some way to manipulate appropriate dimer 
pool balance. As such future work must make all of these considerations when 
attempting to further deconvolute the myriad of interconnected signals possibly 
causative of dimer partner selection. Further work on both understanding dimer 
selection and methods for their manipulation should remain a high priority for the 
future as specific control of dimers may be the key to more appropriate tuning of 
NF-κB signaling in disease states. Moreover, direct subunit manipulation offers 
advantages over potential therapies related to upstream signaling including the 
reduction of the potential for unwanted off target effects that could exacerbate the 
underlying condition or have another unintended off target effect [39]. 
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6.2 The p50 Nuclear localization sequence as a dynamic scaffold for 
the control of gene induction and suppression. 
In addition to the previously described protein-protein interactions occurring 
at or near the NLS, data presented here define the NLS of p50 as the major site of 
interaction with HDAC1. While other possible sites of interaction were predicted in 
silico, the observed near total ablation of p50:HDAC1 interaction upon mutation of 
the VQKRKQK motif strongly supports this region as the critical site of interaction. 
Considering this evidence and borrowing from previous published data, the working 
model proposed here suggests that dimers of p50 at target sites in the nucleus 
serve as a scaffold for numerous epigenetic events [124,127]. Seen in Figure 6.1, 
loops of the ankyrin repeats of IκBα bind a p65 homodimer near the region of the 
p65 NLS. Moreover, the flexibility of the terminal amino acids on this end of p50, if 
similar to p65, may serve as a tether to bind freed epigenetic remodeling 
complexes. The crystal structure of HDAC1 bound to metastasis associated protein 
1 (Mta1) suggests this is a reasonable assumption as in this resolved structure the 
unstructured tail of Mta1 wraps around the catalytic core of HDAC1 and makes 
several contacts along grooves created by external alpha helices of [95]. In a 
similar way the unstructured tail of p50 may be created multiple points of contacts 
around not just HDAC1 but other components of the nuclear epigenetic machinery. 
With this stated, however, the possibility of third party mediators within the 
p50:HDAC1 or other interactors has not been experimentally disproven. Further 
evidence and investigation is needed to ascertain two important unknowns raised 
here. First, is p50 capable of direct recruitment of these numerous co-factors to κB 
sites or are there further intermediates? Secondly, of the many complexes 
potentially capable of being formed on a p50 scaffold, how many of them provide 
meaningful changes to the function of cell in which they are found. Evidence for 
Bcl3 and now HDAC1 strongly suggests these as two direct interactors but whether 
these represent the end of a list or a small subsection of a much larger pool is yet 
to be determined. 
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Crystal structure of a p65 homodimer (beige) dimerization domain bound to IκBβ (blue) 
highlighting the nature of the interaction between the ankyrin repeats as well as the 
unstructured tails of p50 and p65 (PDB ID 1OY3) [124]. 
 
 
 
 
 
 
 
Figure 6.1 Crystal structure of p65 homodimer bound to IκBβ 
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6.3 Interaction with HDAC1 is critical to the active gene repression of 
p50 homodimers 
Evidence provided for the direct interaction of p50 with HDAC1 while 
suggested by two methods relies either on in vitro observation or overexpression. 
This evidence on its own, however, does make a strong case that the site identified 
is indeed where p50 binds HDAC1. Moreover, functional tests by RT-qPCR and 
chemotaxis assay all suggest important regulation by p50 of pro-inflammatory 
genes in an HDAC1-dependent manner. While conclusions in this regard may be 
strengthened by further in vivo work including the verification of a pro-inflammatory, 
cell specific phenotype in genetically modified mice, the data presented robustly 
supports the arguments made regarding the importance and observed effects of a 
loss of HDAC1. One potential weakness in the functional data regarding an 
upregulation of pro-inflammatory genes (Figure 5.8), is that p50 WT is seen 
activating transcription. There is, however, little evidence that suggests that a p50 
overexpression would cause complete suppression of gene transcription in WT 
cells much less the p50 knock outs used in this experiment.  What is clear is that 
p50 is not just a simple repressive molecule but tends toward active repression in 
the absence of signal and that these results are being interpreted as the result of 
the reconstitution of both p50 and the p50:p65 heterodimer which will have potent 
effects on gene transcription.  
6.4 Conclusion 
This collection of work has driven our understanding of NF-κB repression 
and made several advances in our appreciation of the biochemistry of p50. Shown 
through the use of in silico molecular dynamics simulations, p50 may be 
phosphorylated at serine 343 but this residue is also critical for protein stability and 
homodimerization [58]. This collection of data also further elucidates the conserved 
difference in the interfaces of p50 and p65 and demonstrated that mutation in 
interfacial residues may have a significant impact on the affinities of dimers 
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[113,116]. This work has also described the VQKRKQK motif in the NLS of p50 as 
the region responsible for the p50:HDAC1 interaction which exists primarily in 
resting cells. Additionally, loss of most residues due to mutation of the NLS seemed 
to have little to no effect on p50 nuclear localization and calls into question previous 
studies which report this region as essential [112]. Another major observation 
includes the fact that the loss of HDAC1 interaction and its NLS does not seem to 
impact the function of p50 in any way, including its ability to form canonical 
complexes and drive DNA transcription along with p65 in addition to not influencing 
localization. Finally loss of p50:HDAC1 leads to increased promoter acetylation, 
increased transcription of pro-inflammatory genes and increased neutrophil 
chemotaxis all of which cementing HDAC1 as a critical effector in NF-κB signaling 
repression. 
6.5 Future Work 
Given the complexities underscored here and in the literature concerning the 
various intricacies of subunit and cascade activation that leads to multiple 
transcriptional programs, it is clear that there is much still left to be uncovered. Two 
important and related questions that warrant further examination is the role of 
interface residues highlighted in chapter 3 in the section of dimer partners and the 
regulation of interaction factors (such as HDAC1, BCL3, HAT’s etc.) on those base 
line possible subunit combinations.  
Dimerization has always posed a challenge in the NF-κB field as many tools 
and systems developed to date made it impossible to determine the specific 
contributions of each subunit to a particular transcriptional profile. While others 
have noted subunit specific sequence changes that facilitate different dimer 
affinities as well as potential posttranslational modifications which do the same, 
emerging powerful techniques such as CRISPR gene editing may provide an 
alternative method for dissecting the lone and combinatorial effect of residues in 
subunits such as those interface and sites of posttranslational modification 
described in this work. Uncovering the contribution of each subunit and post 
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translational modification and subsequent enzymes responsible would not only 
lead to better understanding of this important transcription factor system but could 
highlight therapeutic targets for many inflammation associated diseases. 
In a similar manner the emerging network surrounding third party interactors 
with subunits still needs exploration. Previously described in the most detail, BCL3 
has been added to the list of p50 homodimer interactors that enhance their function 
[73]. This work now also adds HDAC1 to that list in a similarly robust way. As 
discussed earlier, however, much still needs to be understood regarding the 
relationship these two proteins have with regards to p50 homodimers including the 
conditions of their occupancy on binding sites. In addition, there are undoubtedly 
more third party interactors that adds more specificity to the function of not only 
p50 dimers but those of the other subunit combinations as well. While not an easy 
challenge, mapping this dimer specific interactome of all possible combination 
would provide true insight in the tightly controlled way that NF-κB promotes and 
repressed gene transcription. This understanding would especially be of 
importance to those designing therapeutic to fully understand the wider implications 
of altering pathways or pathways outcomes in an attempt to treat disease.  
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6.6 Summary 
 
• Serine 343 (human) is critical to the stability of p50 and may be a site of 
post translational modification involved in dimer selection. 
• Four conserved differences in the interface of the p50:p65 heterodimer 
impart partial dimer stability and specificity. 
• p50 interacts with HDAC1 via its VQKRKQK NLS motif. 
• Mutation of the p50 NLS motif does not affect DNA binding, dimerization or 
nuclear localization. 
• In the absence of HDAC1, p50 bound promotors show increased 
acetylation. 
• In the absence of HDAC1, p50 bound pro-inflammatory target genes show 
increased expression. 
• Loss of p50:HDAC1 stimulates cells to increase neutrophil chemotaxis 
signals and enhance a pro-inflammatory environment. 
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Chapter 7 Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7.1 petM30 Vector Map 
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Appendix 7.2 pcDNA3 Vector Map 
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Appendix 7.3 Primers used in SDM, RT-qPCR and ChIP Assays 
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Appendix 7.4 Primers used in petM30 cloning and sequencing for 
crystallography constructs. 
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Bacterial Strain Source 
NEB Ultra Competent DH5α New England Biolabs C2987H 
Rosetta 2(DE3)pLysS  Novagen 71401 
BL21 DE3 New England Biolabs C2527H 
Lemo21 New England Biolabs C2528J 
Tunner Novagen 70623 
Arctic Express Agilent 230191 
In-lab generated DH5α Originally New England Biolabs C2987H 
 
Appendix 7.5 Bacterial strains used in production of recombinant 
protein. 
 
 
 
 
 
 
Backbone Insert Tags 
pcDNA3.1 p50 WT Flag 
pcDNA3.1 p50 VQRARQK Flag 
pcDNA3.1 p50 VQAARQK Flag 
pcDNA3.1 p50 AQAARQK Flag 
pcDNA3.1 p50 AQAAAQK Flag 
pcDNA3.1 p50 AQAAAQA Flag 
pcDNA3.1 p50 K365A Flag 
petM30 HDAC1 WT TEV-GST-6xHIS 
petM30 HDAC1 8-378aa TEV-GST-6xHIS 
petM30 p65 TEV-GST-6xHIS 
petM30 p50 WT TEV-GST-6xHIS 
petM30 p50 40-353aa TEV-GST-6xHIS 
 
Appendix 7.6 List of Plasmids Used and Generated 
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